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W
e are delighted to present the first 
Supplement to the journal series Health 
Technology Assessment.  The series is now over 10 
years old and has published more than 400 titles, 
covering a wide range of health technologies in a 
diverse set of applications. In general, the series 
publishes each technology assessment as a separate 
issue within each annual volume. This Supplement 
departs from that format by containing a series 
of shorter articles. These are all products from a 
‘call-off contract’ which the HTA programme holds 
with a range of academic centres around the UK, at 
the universities of Aberdeen, Birmingham, Exeter, 
Liverpool, Sheffield, Southampton and York. These 
centres are retained to provide a highly responsive 
resource which meets the needs of national policy 
makers, notably the National Institute for Health 
and Clinical Excellence (NICE).
Until recently, these HTA Technology Assessment 
Review (TAR) centres provided academic input to 
policy making through independent analyses of 
the impact and value of health technologies. As 
many readers will be aware, the perception that 
the advice NICE provides to the NHS could be 
made more timely has led to the development of 
the ‘Single Technology Appraisal’ process. In this 
approach, manufacturers of technologies, which 
are, in general, pharmaceuticals close to the time 
of launch, submit a dossier of evidence aiming to 
demonstrate effectiveness and cost-effectiveness. 
The independent academic input to NICE’s 
process, which continues to be supported by the 
TAR centres around the UK under contract to the 
HTA programme, is to scrutinise, critique and 
explore this dossier of evidence.
The papers included in this Supplement report on 
the first tranche of this HTA programme funded 
work which, with only one exception, relates to the 
potential use of new drugs for cancer within the 
NHS.
We hope that the summaries of the work carried 
out to inform the development of NICE guidance 
for these technologies will be of interest and value 
to readers. Further details of each of the NICE 
Appraisals are available on the NICE website (www.
nice.org.uk) and we welcome comments on the 
summaries via the HTA website.
Prof. Tom Walley 
Director, NIHR HTA programme 
Editor-In-Chief, Health Technology Assessment
Prof. Ken Stein 
Chair, Editorial Board, Health Technology Assessment
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the the clinical and 
cost-effectiveness of trastuzumab for the treatment 
of primary breast cancer in human epidermal 
growth factor 2 (HER2)-positive women based 
upon a review of the manufacturer’s submission 
to the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The manufacturer’s 
scope restricts the intervention to intravenous 
trastuzumab given for 1 year after surgery and after 
the completion of standard adjuvant chemotherapy, 
and the comparator to standard therapy without 
trastuzumab. The clinical rationale for the duration 
of treatment in the scope is open to question and 
leads to the exclsuion of one potentially relevant 
trial. The submitted evidence reports that the 
3-weekly regimen of trastuzumab produced a 
relative reduction in all-cause mortality of 24–33%. 
Meta-analysis of all available studies based on 12 
months of trastuzumab showed that there was a 
statistically significant 30% relative improvement in 
overall survival using the 3-weekly regimen. A study 
looking at weekly cycles of trastuzumab, excluded 
in the manufacturer’s submission, produced a 
relative reduction in all-cause mortality of 59%, 
which was not statistically significant. All included 
studies showed a statistically significant difference 
in the risk of recurrence or death from any cause 
(disease-free survival), favouring trastuzumab. 
There was a statistically significant increase in the 
relative risk of a serious adverse event in women 
treated with 3-weekly cycles of trastuzumab, with no 
excess toxicity in the study evaluating weekly cycles. 
Estimates of cost-effectiveness provided by the 
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manufacturer were based on data from the HERA 
trial using the 3-weekly regimen of trastuzumab. 
The economic model was a state-transition model 
that compared the lifetime impact of adding 1 
year of trastuzumab therapy to standard care with 
standard care alone. The  initial cost-effectiveness 
estimate was £5687 per additional quality-adjusted 
life-year (QALY) gained, rising to a maximum of 
£8689 upon one-way sensitivity analysis. The base-
case estimate of cost-effectiveness was subsequently 
revised by the manufacturer, resulting in an 
estimated incremental cost per additional QALY 
gained of £2387. A number of assumptions behind 
the manufacturer’s model may be optimistic 
and could mean that the incremental costs per 
QALY gained were underestimated. Additional 
analysis carried out by the evidence review group 
concluded that the incremental cost-effectiveness 
ratio (ICER) is expected to be around £20,000 
to £30,000. The addition of potential long-term 
cardiac events could push the ICER above £30,000, 
although there is no long-term evidence to date 
surrounding this issue. In addition, the small study 
excluded from the manufacturer’s submission raises 
the possibility of an equally effective but shorter 
regimen, incurring lower cost and toxicity and with 
greater patient convenience. The guidance issued 
by NICE in June 2006 as a result of the STA states 
that trastuzumab, given at 3-week intervals for 1 
year or until disease recurrence, is recommended 
as a treatment option for women with early-stage 
HER2-positive breast cancer following surgery, 
chemotherapy and radiotherapy.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of trastuzumab for the treatment of primary breast 
cancer in HER2-positive women.2
Description of the 
underlying health problem
HER2-positive breast cancer is a breast cancer that 
tests positive for human epidermal growth factor 
receptor 2 (HER2). This protein promotes cancer 
cell growth. Cancer cells produce an excess of 
HER2 as a result of gene mutation in about one-
third of cases of breast cancer. HER2-positive breast 
cancers are more aggressive than other types of 
breast cancer and are less responsive to hormone 
treatment.
Scope of the ERG report
No scoping exercise was undertaken by NICE 
for this STA. The scope as defined by Roche 
(the manufacturer of trastuzumab), restricts the 
intervention to intravenous trastuzumab given 
for 1 year after surgery and after the completion 
of standard adjuvant chemotherapy. It restricts 
the comparator to standard therapy without 
trastuzumab, which by implication is NICE’s 
recommended four to eight cycles of anthracycline-
containing chemotherapy postsurgery and 5 years 
of hormonal therapy. The primary outcome is 
defined as disease-free survival (cancer recurrence 
or death from any cause); secondary outcomes 
include overall survival, breast cancer recurrence 
and cardiotoxicity. Economic outcomes include cost 
per life-year gained (LYG) and cost per quality-
adjusted life-year (QALY) gained. 
Methods 
The ERG report comprised a critical review of 
the evidence for the clinical effectiveness and 
cost-effectiveness of the technology based upon 
the manufacturer’s/sponsor’s submission to NICE 
as part of the STA process. In addition, the ERG 
carried out a meta-analysis of trials to derive a 
more precise estimate of treatment effect in terms 
of overall survival, disease-free survival, distant 
recurrence and cardiac toxicity. The ERG also 
critically evaluated the role of a study excluded in 
the manufacturer’s submission (FinHER study3) 
in decision-making. Sensitivity analysis was also 
carried out to evaluate the robustness of the Health Technology Assessment 2009; Vol. 13: Suppl. 1
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manufacturer’s model, as well as the impact of the 
ERG’s revised base-case assumptions.
Results 
Summary of submitted 
clinical evidence
Five relevant phase III trials were identified by 
systematic review: HERA (n = 3387),4 BCIRG-006 
(n = 2148),5 NCCTG N9831 (n = 1615),6 NSABP 
B-31 (n = 1736),6 and FinHER (n = 229).3 The 
published evidence reports that 18 × 3-weekly cycles 
of trastuzumab produced a relative reduction in 
the hazard of all-cause mortality from 24% [hazard 
ratio (HR) 0.76, 95% CI 0.47–1.23; absolute risk 
reduction 0.5%) at a median follow-up of 1 year 
in the HERA trial to 33% (HR 0.67, 95% CI 0.48–
0.93; absolute risk reduction 1.8%) at a median 
follow-up of 2 years in the combined B-31 and 
N9831 analysis. When all studies with available 
data were meta-analysed there was a 30% relative 
improvement in overall survival and this was 
statistically significant at the 5% level (HR 0.70, 
95% CI 0.53–0.92, p = 0.010). The excluded study,4 
which looked at nine weekly cycles of trastuzumab, 
given concurrently with three cycles of docetaxel 
or eight cycles of vinorelbine, produced a relative 
reduction in the hazard of all-cause mortality of 
59% (HR 0.41, 95% CI 0.16–1.08; absolute risk 
reduction 6.9%) at a median follow-up of 3 years 
(the longest follow-up available for any trastuzumab 
schedule). This study had a small sample size and 
was not statistically significant at the 5% level. 
All included studies, at whatever schedule or length 
of follow-up, showed a statistically significant 
difference in the risk of recurrence or death 
from any cause (disease-free survival), favouring 
trastuzumab. The combined HR for 18 × 3-weekly 
cycles was 0.50 (95% CI 0.44–0.57, p < 0.00001). 
In the study evaluating nine weekly cycles the HR 
was 0.42 (95% CI 0.21–0.83, p = 0.01). There was 
a statistically significant (almost sixfold) increase 
in the relative risk (5.54, 95% CI 2.07–14.82, 
p = 0.0007) of a serious life-threatening or fatal 
cardiac event in women treated with 18 three-
weekly cycles of trastuzumab, although this 
represents an absolute risk increase of just 1.6% 
(Figure 1). In the FinHER study evaluating nine 
weekly cycles there was no excess toxicity.3
Summary of submitted cost-
effectiveness evidence
Roche have developed a state-transition cohort 
model to compare the lifetime impact of 1 year of 
adjuvant trastuzumab therapy with no trastuzumab 
following standard chemotherapy. The main data 
source for the model is the Herceptin Adjuvant 
(HERA) trial, an international, multicentre, 
randomised trial on women with HER2-positive 
primary breast cancer, with a median of 1 year 
of follow-up. Outcomes from the HERA trial are 
extrapolated over a lifetime horizon to assess the 
long-term benefits and costs of trastuzumab. The 
model takes into account cardiac toxicity but does 
not consider other adverse events. The health 
states used within the model are considered to be 
appropriate for the required analysis. The cost of 
trastuzumab has been underestimated in the Roche 
submission, along with the cost of monitoring for 
cardiac toxicity. The costs and utilities associated 
with each health state were based upon studies 
carried out by the MEDTAP (Medical Technology 
Assessment and Policy) research centre specifically 
Review:
Comparison:
Outcome:
Study
or sub-category
Trastuzumab
n/N
Control
n/N
RR (random)
95% CI
RR (random)
95% CI
Weight
%
B-31
BC/RG 006
HERA
N9831
31/864
25/1068
9/1694
21/808
5/872
10/1050
1/1693
0/807
6.26 (2.44, 16.02)
2.46 (1.19, 5.09)
8.99 (1.14, 70.92)
42.95 (2.61, 707.77)
34.68
39.69
15.70
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Total (95% CI) 4434 4422 5.54 (2.07, 14.82) 100.00
Trastuzumab for HER2-positive early breast cancer
01 Trastuzumab vs control
04 Grade 3–4 cardiac event or death from heart failure
Total events: 86 (Trastuzumab), 16 (Control)
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Favours
control
Test for heterogeneity: (χ2 = 6.69, df = 3, p = 0.08) I2 = 55.1%
Test for overall effect: z = 3.41 (p = 0.0007)
1000 100 10 0.01 0.1 1
FIGURE 1  Cardiac toxicity. Trastuzumab for the treatment of primary breast cancer in HER2-positive women
4
for the model. These costs appear high relative to 
other recent breast cancer models.8,9
The Roche model estimated that the base-case 
incremental cost-effectiveness ratio (ICER) 
of chemotherapy plus trastuzumab versus 
chemotherapy is £5687 per QALY gained, 
rising to a maximum of £8689 upon one-way 
sensitivity analysis of the parameters. However, 
in the view of the ERG several of the baseline 
costs were underestimated and some of the upper 
or lower parameter values tested within the 
sensitivity analysis were not sufficiently extreme. 
In addition, there was no sensitivity analysis 
around the extrapolation of rate of recurrence 
in the comparator arm and limited sensitivity 
analysis around the relative risk of recurrence 
for trastuzumab. With respect to the probabilistic 
sensitivity analysis the description of uncertainty 
surrounding the mean values of many of the model 
parameters was considered to be insufficient or 
incomplete. However, following responses from 
Roche to queries raised by the ERG in a letter 
dated 8 March 2006 a revised base case of £2387 
was presented by Roche (section 6 of ERG report2). 
This included a correction to an error in the 
original model, which reduced the ICER. Based 
on further sensitivity analysis carried out by the 
ERG (e.g. Figure 2) the ERG conclude that the 
ICER presented by Roche is too low. The combined 
effect of the uncertainties has the potential to 
increase the central estimate of the ICER to 
around £20,000–£30,000 (Figure 3). The addition 
of potential long-term cardiac events could push 
the ICER above £30,000, although the ICER is not 
expected to rise above £35,000–£50,000.
Commentary on the robustness 
of submitted evidence
The model structure is appropriate and allows 
sensitivity analysis to be carried out easily. One-
way sensitivity analysis suggests that variations 
in the majority of the parameters do not have a 
large effect upon the ICER. The baseline ICER is 
relatively modest, such that potential parameter 
NEAT/BR9601
FAC
EBCTCG
Equilavent
EBCTCG
0.89 (se 0.03)
CMF
TAC
E-CMF
FASG
0.7
PACS
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0.70 (0.58, 0.85)
FEC50 FEC100-T FEC100
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0
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1.0
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P
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o
b
a
b
i
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t
y
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Sensitivity analysis 1
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FIGURE 2  Sensitivity analysis around rate of recurrence over time in comparator arm. 
FIGURE 3  Evidence review group’s base case – cost-effectiveness acceptability curve. QALY, quality-adjusted life-year.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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variations are unlikely to increase the ICER beyond 
the currently accepted threshold values. However, 
no sensitivity analysis has been undertaken to 
explore the impact of uncertainty surrounding the 
comparator arm on the ICER. Little sensitivity 
analysis has been carried out around the long-term 
benefits of trastuzumab. Confidence intervals of 
some of the parameters do not adequately describe 
the uncertainty. For instance, the upper values of 
the cost of trastuzumab and cardiac monitoring 
were considered to be unrealistic.
There are a number of major areas of uncertainty. 
Disease-free and overall survival may differ from 
the comparator arm in the model, depending on 
the chemotherapy regimens being used in the UK. 
The benefits of trastuzumab regarding rates of 
recurrence are unknown beyond 3–4 years. There is 
little evidence to date on the effects of trastuzumab 
upon overall survival. There is no evidence on 
the effects of trastuzumab upon long-term cardiac 
dysfunction.
Conclusions 
The following issues have the potential to impact 
on the cost-effectiveness results: the uncertainty 
surrounding the long-term benefits of trastuzumab 
in terms of reduction in the risk of recurrence; the 
extent to which reductions in the rate of recurrence 
will translate into benefits in overall survival; the 
extent to which patients in both the comparator 
arm and the trastuzumab arm are likely to receive 
trastuzumab in the metastatic setting; and the 
uncertainty generated by long-term extrapolation 
of the comparator arm. The combined effect of 
these uncertainties has the potential to increase 
the ICER from below £5000 to around £20,000–
£30,000. The addition of potential long-term 
cardiac events could push the ICER above £30,000 
although there is no long-term evidence to date 
surrounding this issue. 
There are also a number of other important issues 
that are not explicitly taken into account in the 
economic modelling. A small study (the FinHER 
trial,3 n = 229), excluded from the manufacturer’s 
submission, raises the possibility of an equally 
effective but shorter regimen, incurring lower cost 
and toxicity and with greater patient convenience. 
Finally, there are a number of capacity issues 
for the NHS: HER2 testing, the preparation 
and administration of trastuzumab and cardiac 
monitoring will all require the augmentation of 
currently available facilities.
Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in June 2006 states 
that: 
Trastuzumab, given at 3-week intervals for 1 
year or until disease recurrence (whichever is the 
shorter period), is recommended as a treatment 
option for women with early-stage HER2-positive 
breast cancer following surgery, chemotherapy 
(neoadjuvant or adjuvant) and radiotherapy (if 
applicable). 
Cardiac function should be assessed prior to the 
commencement of therapy and trastuzumab 
treatment should not be offered to women who 
have a left ventricular ejection fraction (LVEF) of 
55% or less, or who have any of the following: 
•	 a history of documented congestive heart 
failure 
•	 high-risk uncontrolled arrhythmias 
•	 angina pectoris requiring medication 
•	 clinically significant valvular disease 
•	 evidence of transmural infarction on 
electrocardiograph
•	 poorly controlled hypertension. 
Cardiac functional assessments should be repeated 
every 3 months during trastuzumab treatment. If 
the LVEF drops by 10 percentage (ejection) points 
or more from from baseline and to below 50% 
then trastuzumab treatment should be suspended. 
A decision to resume trastuzumab therapy should 
be based on a further cardiac assessment and a 
fully informed discussion of the risks and benefits 
between the individual patient and their clinician. 
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
and cost-effectiveness of docetaxel for the 
adjuvant treatment of early node-positive 
breast cancer based upon the manufacturer’s 
submission to the National Institute for Health 
and Clinical Excellence (NICE) as part of the 
single technology appraisal (STA) process. The 
manufacturer’s scope restricts the intervention to 
docetaxel in combination with doxorubicin and 
cyclophosphamide (TAC), and the comparator to 
anthracycline-based chemotherapy. Based on the 
BCIRG 001 trial, the submitted evidence shows 
that TAC is associated with superior disease-free 
and overall survival at 5 years compared with the 
anthracycline-based regimen FAC. The absolute 
risk reduction in patients treated with TAC 
compared with those treated with FAC was 7% for 
disease-free survival and 6% for overall survival. 
However, TAC was associated with significantly 
greater toxicity than FAC. There is also evidence 
that docetaxel, in an unlicensed sequential regimen 
FEC100-T, is associated with superior disease-
free and overall survival at 5 years compared with 
FEC100. An economic model was developed by 
the manufacturer based on the BCIRG 001 trial. 
This generated central estimates of the cost per 
life-year gained and cost per quality-adjusted life-
year (QALY) gained of TAC compared with FAC of 
£7900 and £9800 respectively. The manufacturer’s 
submission predicts a cost-effectiveness of 
£15,000–£20,000 per QALY gained for TAC 
compared with E-CMF (epirubicin in sequential 
therapy with cyclophosphamide, methotrexate, and 
HTA 05/53/01
Date of ERG submission: 
March 2006
TAR Centre(s): 
School of Health and Related Research (ScHARR)
List of authors: 
J Chilcott, M Lloyd Jones and A Wilkinson
Contact details: 
Mr Jim Chilcott, University of Sheffield, Regent Court, 
30 Regent Street, Sheffield S1 4DA, UK
Email: j.b.chilcott@sheffield.ac.uk
The research reported in this article of the journal 
supplement was commissioned and funded by the 
HTA programme on behalf of NICE as project number 
05/53/01. The assessment report began editorial 
review in July 2007 and was accepted for publication 
in November 2008. See the HTA programme website 
(www.hta.ac.uk) for further project information. This 
summary of the ERG report was compiled after the 
Appraisal Committee’s review.
The views and opinions expressed therein are those of 
the authors and do not necessarily reflect those of the 
Department of Health.
Discussion of ERG reports is invited. Visit the HTA 
website correspondence forum (www.hta.ac.uk/
correspond).
DOI: 10.3310/hta13suppl1/02Docetaxel for the adjuvant treatment of early node-positive breast cancer
8
fluorouracil), and estimates the cost-effectiveness 
of FEC100-T to be £8200 per QALY compared 
with FEC100. Taking into account a number of 
issues identified by the ERG this may generate 
higher estimates of cost-effectiveness, but these 
are unlikely to exceed £35,000 per QALY gained. 
Importantly, FAC is not commonly used in clinical 
practice in the UK and, therefore, the submitted 
evidence does not indicate whether TAC is superior 
to the anthracycline-based regimens that are 
in common use (FEC or E-CMF). The indirect 
comparisons presented suggest that the economic 
case for TAC in comparison to current UK practice 
may not be proven. The manufacturer’s submission 
failed to record evidence of three serious adverse 
events in patients receiving docetaxel with 
doxorubicin or to mention the concern of the 
European Medicines Agency regarding TAC’s 
long-term adverse events. The guidance issued by 
NICE in June 2006 as a result of the STA states 
that docetaxel, when given concurrently with 
doxorubicin and cyclophosphamide (the TAC 
regimen), is recommended as an option for the 
adjuvant treatment of women with early node-
positive breast cancer.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of docetaxel for the adjuvant treatment of early 
node-positive breast cancer.2
Description of the 
underlying health problem
Breast cancer is the most common cancer among 
women in England and Wales. Around one in 
nine women will be diagnosed with breast cancer 
at some time in their lives. In 2002, 37,134 new 
cases of breast cancer were diagnosed in women 
in England and Wales.3 The risk of breast cancer 
increases with age; over 80% of cases occur in 
women aged over 50.3 
In breast cancer, prognosis is related to a number 
of factors, including the extent of disease 
progression identified at diagnosis or initial 
surgery. 
Scope of the decision problem
The scope of the manufacturer’s submission 
was limited to docetaxel in combination with 
doxorubicin and cyclophosphamide (TAC) for 
the adjuvant treatment of women diagnosed 
with operable node-positive breast cancer (i.e. 
the relevant licensed application), compared 
with anthracycline-based chemotherapy. It thus 
excludes women with high-risk node-negative 
cancers. Such women, who are at intermediate 
risk of recurrence, would, in clinical practice, 
be considered for adjuvant chemotherapy. The 
scope also excludes docetaxel used in sequential 
therapy (i.e. following or preceding several cycles 
of other cytotoxic drugs), although current clinical 
opinion appears to favour such regimens rather 
than combination regimens such as TAC. The 
anthracycline-based regimens in common use in 
the UK at the time of the assessment were FEC 
and E-CMF. The limitation of the comparators to 
anthracycline-based regimens excludes paclitaxel, 
another taxane, which, like docetaxel, is licensed 
for use in the UK as adjuvant therapy for operable 
node-positive breast cancer in sequential therapy 
following treatment with doxorubicin and 
cyclophosphamide. 
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical and cost-effectiveness of 
the technology, based upon the manufacturer’s/
sponsor’s initial submission to NICE and 
subsequent clarification of issues raised by the ERG 
early in the STA process. A narrative critique of the Health Technology Assessment 2009; Vol. 13: Suppl. 1
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submitted evidence was presented. The economic 
model submitted by the manufacturer was analysed 
to investigate the impact of different assumptions 
regarding potential indirect comparisons with UK 
comparator therapies. 
Results 
Summary of submitted 
clinical evidence
There is evidence from a randomised controlled 
trial (RCT) that, compared with the anthracycline-
based regimen FAC, TAC is associated with 
superior disease-free and overall survival at 5 years 
(HR 0.72, 95% CI 0.59–0.88, p = 0.001 versus HR 
0.70, 95% CI 0.53–0.91, p = 0.008).4 The absolute 
risk reduction at 5 years in patients treated with 
TAC compared with those treated with FAC was 7% 
for disease-free survival and 6% for overall survival, 
and the number of patients who had to be treated 
with TAC rather than FAC for one additional 
patient to benefit was 14 for disease-free survival 
and 17 for overall survival. However, TAC was 
associated with significantly greater toxicity than 
FAC. 
There is also RCT evidence that a sequential 
regimen, FEC100-T, in which docetaxel is used 
after the anthracycline-based regimen FEC100, is 
associated with superior disease-free and overall 
survival at 5 years (adjusted HR 0.83, 95% CI 0.69–
0.99, p = 0.041 versus HR 0.77, 95% CI 0.59–1.00, 
p = 0.05) compared with FEC100.5 The estimated 
absolute risk reduction at 5 years in patients treated 
with FEC100-T compared with those treated 
with FEC100 was 5.1% for disease-free survival 
and 4.0% for overall survival, and the number of 
patients who had to be treated with FEC100-T 
rather than FEC100 for one additional patient to 
benefit was 20 for disease-free survival and 25 for 
overall survival. 
Summary of submitted cost-
effectiveness evidence
An economic model was developed by the 
manufacturer, based primarily on the single trial 
BCIRG 001.4 This submission model generates 
central estimates of the cost per life-year gained 
and cost per quality-adjusted life-year (QALY) 
gained of TAC compared with FAC of £7900 and 
£9800 respectively. 
The manufacturer’s submission predicts a cost-
effectiveness of £15,000–£20,000 per QALY 
gained for TAC compared with E-CMF (epirubicin 
in sequential therapy with cyclophosphamide, 
methotrexate, and fluorouracil). This estimate was 
based upon an indirect comparison of absolute 
disease-free survival rates. 
Based upon the RCT of FEC100-T compared 
with FEC100, the manufacturer’s submission 
estimates the cost-effectiveness of FEC100-T to be 
£8200 (£3500–£56,000) per QALY compared with 
FEC100. Only four of the six potentially relevant 
studies reported overall survival and/or disease-free 
survival (Table 1).
Commentary on the robustness 
of submitted evidence
The ERG identified four other potentially relevant 
studies that do not meet the inclusion criteria in 
full, which were missed by the manufacturer in 
their literature search. These are the ECOG 2197,6 
GEICAM 9805,7 USO 97358 and RAPP 019 studies.
The submitted clinical evidence depends primarily 
on an interim analysis from one trial, BCIRG 
001, which uses docetaxel in its licensed regimen 
(TAC).4 This is a large study carried out in a 
population that appears to be representative of 
the population for whom adjuvant docetaxel is 
licensed and who are expected to be eligible to 
receive it. However, there is no evidence that 
the study outcome assessors were blinded to 
treatment allocation, although the US Food and 
Drug Administration (FDA) recommends such 
blinding when disease-free survival is measured 
and considers it necessary to minimise bias in the 
assessment of drug toxicity. FAC, the anthracycline-
based regimen used as the comparator in the trial, 
is not in common use in the UK, where FEC and 
E-CMF predominate. The submitted evidence does 
not therefore indicate whether TAC is superior 
to the anthracycline-based regimens that are in 
common use. 
No evidence of systematic bias has been found in 
the primary economic analysis of TAC compared 
with FAC presented within the manufacturer’s 
submission. It is the ERG’s opinion that a revised 
model taking into account a number of modelling 
issues identified by the ERG may generate higher 
estimates of cost-effectiveness (Table 2), but it is 
unlikely that these estimates would exceed £35,000 
per QALY gained. The manufacturer’s submission 
presents a probabilistic sensitivity analysis of 
uncertainty in the economic estimates; the certainty 
in the cost-effectiveness estimates is overestimated.Docetaxel for the adjuvant treatment of early node-positive breast cancer
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Conclusions
Docetaxel has been licensed for use in combination 
with doxorubicin and cyclophosphamide (TAC) for 
the adjuvant treatment of women diagnosed with 
operable node-positive breast cancer. Evidence 
from a large RCT demonstrates that TAC is 
superior to the anthracycline-based FAC regimen 
in terms of disease-free and overall survival at 5 
years. However, the same evidence suggests that 
TAC is associated with significantly greater toxicity 
than FAC. Importantly, FAC is not commonly used 
in clinical practice in the UK. The most common 
adjuvant chemotherapy regimens currently in use 
in the UK are FEC, using an epirubicin dose of 
75 mg/m2 or greater, or E-CMF. FAC has not been 
demonstrated to be superior to these anthracycline 
regimens. 
The manufacturer’s submission to NICE failed 
to record the premature termination of the 
French RAPP 01 trial following three fatal or life-
threatening adverse events in patients receiving 
docetaxel with doxorubicin. Furthermore, the 
submission does not mention the concern of the 
European Medicines Agency (EMEA) regarding 
TAC’s long-term adverse events, as a result of 
which intensive monitoring for cardiotoxicity, 
secondary leukaemia and serious gastrointestinal 
toxicity is ongoing. 
TABLE 2  Economic results for TAC compared with FAC from an adjusted model
(a) Estimates of costs and outcomes
TAC FAC Incremental
Costs (deterministic mean per patient)
Cost of chemotherapy and 
administration
£7173 £1263 £5910
Cost of supportive G-CSF £963 £353 £609
Cost of managing adverse 
events
£1521 £749 £772
Monitoring cost for patients in 
remission
£769 £737 £32
Cost of treatment for 
relapsing patients
£5482 £6042 –£561
Total expected cost £15,908 £9145 £6763
Outcomes (deterministic)
Patients discontinuing because 
of adverse events (%)
6.04 1.07 4.97
Life-years (mean per patient) 11.238 10.501 0.736
QALYs (mean per patient) 8.798 8.223 0.575
FAC, fluorouracil, doxorubicin and cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; QALYs, quality-
adjusted life-years; TAC, docetaxel with doxorubicin and cyclophosphamide.
(b) Incremental cost-effectiveness ratio (ICER) estimates
Point estimate of mean 95% Confidence interval
Deterministic Probabilistica Lower Upper
Incremental cost/LYG £9187 £7932 £7289 £8641
Incremental cost/QALY £11,760 £9760 £7805 £15,561
LYG, life-years gained; QALY, quality-adjusted life-year.
a  The probabilistic results reflect the most recent run of the probabilistic simulation. If alternative analyses have been made 
without rerunning the probabilistic model they will not reflect the current analysis.Docetaxel for the adjuvant treatment of early node-positive breast cancer
12
FIGURE 1  Indirect comparisons. CMF, cyclophosphamide, methotrexate and fluorouracil; E-CMF, epirubicin with cyclophosphamide, 
methotrexate and fluorouracil; FAC, fluorouracil, doxorubicin and cyclophosphamide; TAC, docetaxel with doxorubicin and 
cyclophosphamide.
There also exists RCT evidence that docetaxel, in 
an unlicensed sequential regimen FEC100-T, is 
associated with superior disease-free and overall 
survival at 5 years compared with FEC100. 
The health economic model submitted by 
Sanofi-aventis estimates that TAC has a cost-
effectiveness in the order of £10,000 per QALY 
gained compared with FAC. Indirect comparisons 
presented within this review (Figure 1) suggest 
that the economic case for TAC in comparison to 
current UK practice is not proven. As part of the 
unlicensed FEC100-T regimen, the manufacturer’s 
submission estimates that the cost-effectiveness 
for docetaxel is in the order of £10,000 per QALY 
gained compared with FEC100, a comparator that 
is currently used in the UK. 
The relevance of the cost-effectiveness estimates 
put forward in the manufacturer’s submission 
depends on subjective judgments regarding the 
likely superiority of TAC over FEC75–100 or 
E-CMF (Table 3). 
Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in June 2006 states 
that: 
Docetaxel, when given concurrently with 
doxorubicin and cyclophosphamide (the TAC 
regimen) as per its licensed indication, is 
recommended as an option for the adjuvant 
treatment of women with early node-positive breast 
cancer.
NEAT/BR9601
FAC
EBCTCG
Equilavent
EBCTCG
0.89 (se 0.03)
CMF
TAC
E-CMF
FASG
0.7
PACS
0.83 (0.69, 0.99)
0.70 (0.58, 0.85)
FEC50 FEC100-T FEC100
BCIRG01
0.72 (0.59, 0.88)
TABLE 3  Relative risk of disease-free survival, TAC versus E-CMF, for a range of ICER/QALY values
ICER threshold (£/QALY) % Responders in E-CMF arm
Average relative monthly hazard of 
relapse over 5 years
£10,000 87.9 0.75
£20,000 92.3 0.84
£30,000 93.8 0.88
£40,000 94.7 0.90
£50,000 95.2 0.91
£60,000 95.5 0.92
£70,000 95.8 0.93
£100,000 96.2 0.95
E-CMF indirect estimate 0.92
E-CMF, epirubicin with cyclophosphamide, methotrexate and fluorouracil; ICER, incremental cost-effectiveness ratio; QALY, 
quality-adjusted life-year; TAC, docetaxel with doxorubicin and cyclophosphamide.Health Technology Assessment 2009; Vol. 13: Suppl. 1
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
13
Acknowledgements 
The authors would like to thank: Professor R 
Coleman, Head of Clinical Oncology, Cancer 
Research Centre, Weston Park Hospital, Sheffield; 
Dr J Brown, Lecturer in Clinical Oncology, Weston 
Park Hospital, Sheffield; Dr David Dodwell, 
Consultant Oncologist, Cookridge Hospital, Leeds; 
Dr Gregory Wilson, Consultant Oncologist, the 
Christie Hospital, Manchester; and Mr P Golightly, 
Director of Trent Medicines Information Service, 
Leicester, who all acted as clinical advisors in this 
project. The authors would also like to thank Gill 
Rooney, Project Administrator, for her help with 
formatting the document, setting up meetings and 
liaising with the clinical advisors.
Key references
1.  National institute for Health and Clinical 
Excellence. Guide to the single technology (STA) process. 
19 September 2006. URL: www.nice.org.uk/page.
aspx?o=STAprocessguide.
2.  Chilcott J, Lloyd Jones M, Wilkinson A. Docetaxel for 
the adjuvant treatment of early node-positive breast cancer: 
a single technology appraisal. Evidence review group 
single technology appraisal for NICE. 7 March 2006. 
URL: www.nice.org.uk/Guidance/TA109.
3.  Cancer Research UK. UK breast cancer incidence 
statistics. 2006. URL: info.cancerresearchuk.org/
cancerstats/types/breast/incidence/.
4.  Martin M, Pienkowski T, Mackey J, Pawlicki M, 
Guastalla JP, Weaver C, et al. Adjuvant docetaxel 
for node-positive breast cancer. N Engl J Med 
2005;352:2302–13.
5.  Roche H, Fumoleau P, Spielman M, Canon J-L, 
Delozier T, Kerbrat P, et al. 6 cycles of FEC 100 
followed by 3 cycles of docetaxel for node-positive 
breast cancer patients: analysis at 5 years of the 
adjuvant PACS 01 trial. Slide presentation, San 
Antonio Breast Cancer Symposium, December 
2004.
6.  Goldstein L, O’Neill A, Sparano J, Perez E, Shulman 
L, Martino S, et al. E2197: phase III AT (doxorubicin/
docetaxel)  vs.  AC  (doxorubicin/cyclophosphamide) 
in the adjuvant treatment of node positive and high 
risk node negative breast cancer. Proc Am Soc Clin 
Oncol 2005; abstract 512.
7.  Martin M, Lluch A, Segui MA, Anton A, Ruiz A, 
Ramos M, et al. Prophylactic growth factor (GF) 
support with adjuvant docetaxel, doxorubicin, 
and cyclophosphamide (TAC) for node-negative 
breast cancer (BC): an interim safety analysis of the 
GEICAM 9805 study. Proc Am Soc Clin Oncol 2004; 
abstract 620.
8.  Jones SE, Savin MA, Holmes FA, O’Shaughnessy 
JA, Blum JL, Vukelja SJ, et al. Final analysis: TC 
(docetaxel/cyclophosphamide, 4 cycles) has a 
superior disease-free survival compared to standard 
AC (doxorubicin/cyclophosphamide) in 1016 
women with early stage breast cancer. San Antonio 
Breast Cancer Symposium, December, 2005.
9.  Brain EG, Bachelot T, Serin D, Kirscher S, 
Graic Y, Eymard JC, et al. Life-threatening 
sepsis associated with adjuvant doxorubicin plus 
docetaxel for intermediate-risk breast cancer. JAMA 
2005;293:2367–71.Health Technology Assessment 2009; Vol. 13: Suppl. 1
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
15
The use of paclitaxel in the management of early 
stage breast cancer 
S Griffin,* G Dunn, S Palmer, K Macfarlane, S Brent, A Dyker, 
S Erhorn, C Humphries, S White, W Horsley, L Ferrie  
and S Thomas
Centre for Health Economics, University of York and Regional Drug and Therapeutics Centre, 
Newcastle, UK
*Corresponding author
Declared competing interests of authors: none. Mark Sculpher – a member of the Evidence Review 
Group, who did not participate in this review – has financial links with a consultancy which has undertaken 
work for BMS, although not relating to paclitaxel.
HTA 05/54/01
Date of ERG submission: 
March 2006
TAR Centre(s): 
Centre for Health Economics (CHE), University of York
List of authors: 
S Griffin, G Dunn, S Palmer, K Macfarlane, S Brent, 
A Dyker, S Erhorn, C Humphries, S White, W Horsley, 
L Ferrie and S Thomas
Contact details: 
Ms Susan Griffin, Centre for Health Economics (CHE), 
University of York, York YO10 5DD, UK
Email: scg3@york.ac.uk
The research reported in this article of the journal 
supplement was commissioned and funded by the 
HTA programme on behalf of NICE as project number 
05/54/01. The assessment report began editorial 
review in July 2007 and was accepted for publication 
in November 2008. See the HTA programme website 
(www.hta.ac.uk) for further project information. This 
summary of the ERG report was compiled after the 
Appraisal Committee’s review.
The views and opinions expressed therein are those of 
the authors and do not necessarily reflect those of the 
Department of Health.
Discussion of ERG reports is invited. Visit the HTA 
website correspondence forum (www.hta.ac.uk/
correspond).
Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of paclitaxel in the management 
of early stage breast cancer based upon the 
manufacturer’s submission to the National 
Institute for Health and Clinical Excellence 
(NICE) as part of the single technology appraisal 
(STA) process. The scope was not clearly defined 
in the manufacturer’s submission. Two of the 
three clinical trials included in the submission 
report showed that the addition of four cycles 
of paclitaxel to four cycles of doxorubicin and 
cyclophosphamide (AC-P) resulted in modest 
improvements in the two end points of disease-
free survival (DFS) and overall survival (OS). The 
third unpublished study evaluating four cycles of 
AC followed by paclitaxel or docetaxel in breast 
cancer did not show any statistically significant 
differences in DFS or OS between any group. The 
economic evaluation of paclitaxel for adjuvant 
therapy in early breast cancer was based on two of 
the three trials submitted as clinical evidence and 
used a probabilistic Markov state-transition model. 
The measure of health benefit was quality-adjusted 
life-years (QALYs) and the model included direct 
costs using a UK NHS perspective. The primary 
analysis compared AC-P with four cycles of AC. 
The reported incremental cost-effectiveness 
ratio (ICER) for this comparison was £4726 per 
additional QALY for AC-P compared with four 
cycles of AC. The submission did not include a 
DOI: 10.3310/hta13suppl1/03The use of paclitaxel in the management of early stage breast cancer
16
systematic review for clinical or cost-effectiveness 
evidence. As a result, potentially relevant trials 
and previously published studies were omitted. 
The main comparator used did not represent 
standard care in the UK NHS and a large number 
of relevant comparators were omitted, including 
docetaxel. The manufacturer did not consider 
potentially important patient subgroups defined 
by baseline risk, and the cost-effectiveness result 
in the average overall patient population may 
conceal important variation between subgroups. 
Overall, although the economic model may 
have indicated that the addition of four cycles of 
paclitaxel to four cycles of AC may be cost-effective 
compared with providing four cycles of AC only, 
this comparison is not informative to current 
clinical practice in the UK NHS. In the context of 
this review it is not possible for the ERG to predict 
the cost-effectiveness of paclitaxel compared with 
more appropriate, and potentially more effective, 
relevant comparators. The guidance issued by 
NICE in July 2006 as a result of the STA states that 
paclitaxel is not recommended as an option for 
the adjuvant treatment of women with early node-
positive breast cancer.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
The single technology appraisal (STA) process of 
NICE is specifically designed for the appraisal 
of a single product, device or other technology, 
with a single indication, for which most of the 
relevant evidence lies with one manufacturer 
or sponsor.1 Typically, it is used for new 
pharmaceutical products close to launch. The 
principal evidence for an STA is derived from a 
submission by the manufacturer/sponsor of the 
technology. In addition, a report reviewing the 
evidence submission is submitted by the evidence 
review group (ERG), an external organisation 
independent of NICE. This paper presents a 
summary of the ERG report for the STA on the 
use of paclitaxel in the management of early stage 
breast cancer.2
Description of the 
underlying health problem
In England and Wales breast cancer is the most 
common malignancy and cause of cancer mortality 
in women,3–5 with 39,175 new cases of breast 
cancer registered in 2003,4–6 representing a crude 
incidence rate of 74 per 100,000 population. 
In the same year over 11,000 women died of 
breast cancer.3–6 This is a cancer that affects 
predominantly middle-aged to older women. The 
incidence of new cases in 2003 in women younger 
than 30 years was less than 0.4% and the incidence 
in men represented less than 1% of all new cases.4–6 
More than 80% of new cases are diagnosed in 
women aged 50 and over,3,4,6 with the peak age 
range for diagnosis in women being 55–59 years 
(5395 out of 38,864 new cases in 2003).4,6 
The 5-year age-standardised relative survival rate 
up to the end of 2001 for adult female patients 
(15–99 years) diagnosed with breast cancer between 
1996 and 1999 in England and Wales was 77.5%, 
with a trend towards increasing rates of survival 
over the years.7 
An invasive breast cancer is one in which there is 
dissemination of cancer cells outside the basement 
membrane of the ducts and lobules into the 
surrounding adjacent normal tissue.8 The presence 
or absence of involved axillary lymph nodes is the 
single best predictor of survival in breast cancer, 
and important treatment decisions are based on it. 
Both the number of involved nodes and the level 
of nodal involvement predict survival from breast 
cancer.9 When invasive breast cancer is diagnosed 
the extent of the disease should be assessed and the 
tumour staged. The two staging classifications in 
current use are the tumour node metastases (TNM) 
system and the International Union Against Cancer 
(UICC) system, which incorporates the TNM 
classification. Prognosis in breast cancer relates to 
the stage of the disease at presentation.8
Data published in 200310 indicated a prevalence 
of early stage node-positive breast cancer (T1–3, 
N+, M0) in two regional UK populations (n = 559) 
of approximately 21% of all presenting breast 
cancers; the same study reported a pan-European 
(n = 4478) incidence rate of 31%. An earlier (1997) 
UK study (n = 1440) reported that 49.8% of all 
presenting breast cancers were node positive at the 
time of diagnosis.11Health Technology Assessment 2009; Vol. 13: Suppl. 1
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When surgery is considered appropriate treatment 
for breast cancer, a number of options are available, 
with differing levels of breast tissue conservation. 
When chemotherapy is administered after surgery 
of any type it is known as adjuvant chemotherapy. 
When chemotherapy is administered before surgery 
it is known as neoadjuvant chemotherapy.12
Ensuring that adjuvant therapy is always offered 
to women with primary breast cancer when 
appropriate could reduce recurrence and improve 
survival rates.13 In 2002, NICE recommended 
that almost all patients with invasive breast cancer 
should be offered adjuvant systemic therapy 
(hormone therapy and/or chemotherapy).13 
Women at intermediate or high risk of recurrence, 
dictated by primary tumour size, extent of nodal 
involvement and tumour grade, who have not 
had neoadjuvant chemotherapy should normally 
be offered four to eight cycles of multiple-agent 
chemotherapy that includes an anthracycline.13 
Scope of the ERG report
The ERG report critically evaluated the 
evidence submission from Bristol-Myers Squibb 
Pharmaceuticals (BMS) on the clinical and cost-
effectiveness of paclitaxel (Taxol®) for adjuvant 
treatment of early breast cancer.14 The perceived 
aim of the BMS submission was to evaluate the 
clinical and cost-effectiveness of paclitaxel for the 
licensed indication of the treatment of early stage, 
operable, node-positive breast cancer following 
four cycles of anthracycline and cyclophosphamide 
therapy. The licensed dose is 175 mg/m2 every 3 
weeks for four courses. Additionally, paclitaxel is 
licensed for treating ovarian cancer, advanced non-
small cell lung cancer and AIDS-related Kaposi’s 
sarcoma. Paclitaxel is manufactured in the UK as 
Taxol (BMS) and is now also available generically 
(from Mayne Pharma). The list prices at time of 
writing are comparable, with prices of the generic 
drug being £112.20, £336.60 and £1009.80 
and prices of Taxol being £116.05, £347.82 and 
£1043.46 for the 5-ml, 16.7-ml and 50-ml vials 
respectively.15
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical and cost-effectiveness of 
the technology based upon the manufacturer’s/
sponsor’s submission to NICE as part of the STA 
process. 
This report identifies the submission’s strengths 
and weaknesses, supplemented, where appropriate, 
with the ERG’s own analysis. Clinical experts were 
asked to advise the ERG to help inform the review.
As the scope for this STA was not clearly defined in 
the BMS submission, and BMS did not summarise 
the decision problem, the ERG made the decision 
to look at the scope based on the licensed 
indication, that is, the use of paclitaxel for the 
treatment of node-positive breast cancer following 
anthracycline and cyclophosphamide therapy.
In view of the lack of a systematic review in the 
manufacturer’s submission, a full detailed search 
needed to be undertaken as part of the ERG 
report. Thus, the ERG report included a detailed 
systematic search for studies and a critical analysis 
of relevant trials, regardless of whether the BMS 
submission had included them or not. It included 
a summary of the main points from any systematic 
reviews found, and a review of the main points 
from three sets of international guidelines included 
in the BMS submission.
The economic model included in the submission 
was reviewed on the basis of the manufacturer’s 
report and by direct examination of the electronic 
model. The critical appraisal was conducted with 
the aid of a checklist for assessing the quality of 
economic evaluations16 and a narrative review to 
highlight key assumptions and possible limitations. 
This was a pilot STA and processes were not in 
place to give the manufacturer the opportunity 
to provide revised analyses to address limitations 
identified by the ERG during the course of the 
review process. Therefore, additional analyses 
were undertaken by the ERG to provide further 
information on areas that the ERG considered were 
not sufficiently dealt with in the manufacturer’s 
submission. The additional work undertaken 
by the ERG was intended to provide additional 
information on the qualitative impact of identified 
limitations. Given the restricted nature of 
these additional analyses only three areas were 
considered:
•	 subgroup analysis
•	 sensitivity analysis
•	 additional comparator.
It should be noted that the analyses into 
these areas were selective and that the revised 
economic analyses were undertaken to examine 
the robustness of the manufacturer’s own model The use of paclitaxel in the management of early stage breast cancer
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to alternative assumptions. These analyses are 
clearly subject to the same major limitations as the 
economic model. The results should therefore be 
taken only as indicative of the potential impact of 
these gaps in the manufacturer’s submission.
Results 
Summary of submitted 
clinical evidence
Of the three clinical trials included in the 
submission report two were fully published.17,18 
These trials aimed to determine whether four 
cycles of paclitaxel following four cycles of 
doxorubicin and cyclophosphamide (AC-P) would 
prolong disease-free survival (DFS) and overall 
survival (OS). Improvements of 5% [hazard ratio 
(HR) 0.83, 95% CI 0.73–0.94] and 4.2% (HR 0.83, 
95% CI 0.72–0.95) in DFS and 4% (HR 0.82, 
95% CI 0.71–0.95) and 0.8% (HR 0.93, 95% CI 
0.78–1.12) in OS were seen in the two published 
trials. Both showed that the addition of four cycles 
of paclitaxel to four cycles of AC chemotherapy 
resulted in modest improvements in these two end 
points. The unpublished study19 evaluated four 
cycles of AC followed by paclitaxel or docetaxel 
in breast cancer. This trial had insufficient data 
presented to fully assess the validity of the study, 
but it did show that there were no statistically 
significant differences in DFS or OS between any 
group.
Summary of submitted cost-
effectiveness evidence
The submission included a de novo economic 
evaluation of paclitaxel for adjuvant therapy in 
early breast cancer, which the manufacturer’s 
stated was based on two17,19 of the three trials 
submitted as clinical evidence. Of the explicitly 
included trials, one was fully published and the 
other was unpublished. A probabilistic Markov 
state-transition model was used to compare the 
cost-effectiveness of the treatment strategies 
included in the two clinical trials (Figure 1). The 
measure of health benefit was quality-adjusted 
life-years (QALYs) and the model included direct 
costs using a UK NHS perspective. The primary 
analysis compared AC-P with four cycles of AC. 
The reported incremental cost-effectiveness 
ratio (ICER) for this comparison was £4726 per 
additional QALY for AC-P compared with four 
cycles of AC. A summary of the manufacturer’s 
economic evaluation is provided in Table 1.
Commentary on the robustness 
of submitted evidence
The sections containing descriptions of individual 
studies did accurately reflect the data presented 
within the clinical trials that were considered in the 
manufacturer’s submission. The overall economic 
model structure was appropriate for the decision 
problem, and the data sources used to inform 
the model were appropriate from a UK NHS 
perspective.
The ERG felt that the BMS submission was 
generally of poor quality with key omissions. The 
major flaw in the submission was the absence of 
a systematic literature review, as instructed by 
NICE in the draft guidance.20 BMS limited the 
clinical effectiveness review in the submission 
to three studies, and it was unclear without the 
ERG undertaking a full systematic review whether 
they had considered all of the relevant literature. 
This same selective use of available evidence was 
Initial
Local
Regional
Distant
Death due
Death due
Recurrence
FIGURE 1  Schematic of Markov model submitted by Bristol-Myers Squibb Pharmaceuticals.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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TABLE 1  Summary of manufacturer’s economic evaluation
Assumption Source/justification
Model Markov state-transition model with lifetime 
horizon, cycle length of 1 year
None provided
Natural history Equivalent to AC arm of single randomised trial. 
Baseline risk assumed constant after year 7 
(maximum follow-up in trial)
Baseline data taken from CALGB 9344.17 
Justification for constant risk after year 7 based 
on Bonadonna et al.,23 who compared CMF with 
no treatment, but no corresponding statements 
found in original paper
Treatment effect on 
DFS
Lifetime treatment effect Probability of recurrence based on CALGB 
934417 and NABCI E1199.19 No justification 
provided for lifetime treatment effect
Treatment effect on 
OS
Location of recurrence based on excluded 
clinical trial NSABP-B28
Mamounas et al.18
Risk of progression following a recurrence 
independent of treatment received and based 
on a previous economic study rather than OS in 
included trials
Johnston.24 Manufacturers state belief that OS 
from trials would overestimate survival and 
would not allow recognition of costs and quality 
of life implications associated with progression
Adverse events Only considers the costs of managing 
neutropenia. All febrile neutropenia is 
hospitalised and treated with 14-day course 
of G-CSF. All neutropenia assumed to occur 
in first cycle of treatment and be prevented in 
subsequent cycles by G-CSF. No attempt to 
quantify the potential impact of side effects on 
quality of life
Probability of neutropenia based on CALGB 
934417 and NABCI E1199.19 No justification for 
inclusion or exclusion of adverse events
Health-related quality 
of life
External utility estimates assigned to acute-phase 
period and the main health states. Utility during 
acute phase assumed to be the same for all 
chemotherapies. Utility for distant recurrence 
assumes that it is treated with second-line 
chemotherapy
Abstract by Sorensen et al.25 No justification 
provided for selection of data source
Treatment costs Average patient weighs 70 kg with body surface 
area of 1.7 m2. Cost of 1-hour chemotherapy 
administration assumed equal to one outpatient 
visit. Cost of additional hours required for 
administration adjusted on the basis of US costs
BNF 50.15 No justification provided for approach 
used to cost of administration
Health state costs Primary surgery based on that received in 
CALGB 9344. Death due to breast cancer incurs 
palliative care cost but death due to other causes 
does not
Johnston24 
Discount rates 3.5% for health outcomes and costs In accordance with NICE guidance26
AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate and fluorouracil; DFS, disease-free survival; 
G-CSF, granulocyte colony-stimulating factor; OS, overall survival.
apparent in the economic evaluation. There was 
a tendency throughout the trials section to refer 
to relative risk rather than absolute risk, and 
relevant p-values were not quoted. This had the 
effect of exaggerating any possible benefits of 
treatment. Although the trial evidence around 
paclitaxel appears to show modest benefit, the 
trials themselves may not be directly applicable to 
the clinical situation that these patients are likely to 
face.
A further shortcoming of the submission was in not 
clearly defining the choice of comparator(s). This 
is important in determining relative efficacy and, if 
not clearly stated, affects the underlying discussions 
throughout the document. The comparators that 
were included in the cost-effectiveness analysis were 
not considered by the ERG to represent current 
treatment in the UK NHS or relevant licensed 
alternatives, and four cycles of AC may be regarded 
as a weak comparator in this patient population.The use of paclitaxel in the management of early stage breast cancer
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The submission did not consider identifiable 
subgroups of patients defined by prognostic factors 
that strongly influence the baseline risk of future 
events. Instead, the results were presented for 
the average patient recruited to the clinical trials 
included in the analysis, and this may conceal wide 
variation in the cost-effectiveness of paclitaxel 
according to baseline risk. The ERG attempted to 
highlight the potential impact of different patient 
characteristics on both DFS and the improvement 
in outcomes from different treatment options. They 
used data from Adjuvant! Online, a web-based 
decision aid that predicts 10-year breast cancer 
outcomes with and without adjuvant therapy.21,22 
Table 2 presents a comparison of 10-year DFS rates 
from the manufacturer’s model with those from 
Adjuvant! Online. 
There were a number of typographical errors, 
minor discrepancies in data and modelling 
errors in the submission report and a number of 
statements throughout that were not supported by 
valid references. Overall, the submission report was 
not of a high quality. See Table 3 for a comparison 
of the submission model with a NICE reference 
case. Consequently, parts of the submission needed 
to be repeated by the ERG and a lot more time was 
spent on areas that should have been appropriately 
completed by BMS.
Conclusions
The submission did not include a systematic review 
for clinical or cost-effectiveness evidence. As a 
result, potentially relevant trials and previously 
published studies were omitted. The main 
comparator used did not represent standard care 
in the UK NHS and a large number of relevant 
comparators were omitted, including docetaxel, 
another taxane, as licensed for the same indication. 
The manufacturer did not consider potentially 
important patient subgroups defined by baseline 
risk, and the cost-effectiveness result in the average 
overall patient population may conceal important 
variation between subgroups.
Overall, although the economic model may 
have indicated that the addition of four cycles of 
paclitaxel to four cycles of AC may be cost-effective 
compared with providing four cycles of AC only, 
this comparison is not informative to current 
clinical practice in the UK NHS. In the context of 
this review it is not possible for the ERG to predict 
the cost-effectiveness of paclitaxel compared with 
more appropriate, and potentially more effective, 
relevant comparators such as six cycles of FAC 
or the licensed indication of docetaxel. It is 
therefore impossible for the ERG to predict what 
effect including these comparators would have on 
the cost-effectiveness of paclitaxel for adjuvant 
treatment of early breast cancer.
Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in July 2006 states 
that:
Paclitaxel is not recommended as an option for 
the adjuvant treatment of women with early node-
positive breast cancer.27
TABLE 2  Percentage of patients without recurrence after 10 years: comparison of manufacturer’s model and Adjuvant! Online
 
AC/first generation 
(%)
AC-P3/second 
generation (%)
Percentage point difference 
between treatment
Manufacturer’s model 47 53 6
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ERG base case 48.1 55.2 7.1
ER status negative 39.9 47.5 7.6
Grade 3 41.9 49.4 7.5
Size > 5.0 cm 35.7 43.5 7.8
> Nine positive nodes 31.2 39.1 7.9
Low risk 82.9 85.3 2.4
High risk 9.8 15.7 5.9
AC, doxorubicin and cyclophosphamide; AC-P , paclitaxel with doxorubicin and cyclophosphamide; ER, oestrogen receptor; 
ERG, evidence review group.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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TABLE 3  Comparison of manufacturer’s submission with NICE reference case
Element of assessment Reference case Manufacturers submission
Defining the decision 
problem
N/A for STA Treatment of interest was the licensed form of 
paclitaxel. Model considers a hypothetical cohort of 
women aged 50 years with operable node-positive 
breast cancer (based on patients recruited to 
Henderson et al17)
Comparator Alternative therapies routinely used 
in the NHS
No. Four cycles of AC used as the comparator. This is 
unlikely to represent standard treatment in the UK for 
this high-risk patient population
Perspective on costs NHS and PSS Yes. However, some relevant categories of cost are 
omitted from the analysis (e.g. premedication)
Perspective on outcomes All health effects on individuals Yes. However, model does not include differential utility 
impact related to toxicity while receiving treatment
Types of economic 
evaluation
Cost-effectiveness analysis Yes
Synthesis of evidence on 
outcomes
Based on a systematic review No
Measure of health benefits Quality-adjusted life-years (QALYs) Yes
Description of health states 
for calculation of QALYs
Health states described using a 
standardised and validated generic 
instrument
No. Utilities based on standard gamble methodology. 
Health state descriptions not publicly available
Methods of preference 
elicitation for health state 
valuation
Choice-based method, for example 
time trade-off, standard gamble (not 
rating scale)
Yes
Source of preference data Representative sample of the public No. Sample consisted of patients: 67 postmenopausal 
women aged 55–70 years in the UK (n = 23) and US 
(n = 44) who had a history of stage 1 or 2 operable 
early breast cancer 
Discount rate An annual rate of 3.5% on both costs 
and health effects
Yes
Equity provision An additional QALY has the same 
weight regardless of the other 
characteristics of the individuals 
receiving the health benefit
Yes
AC, doxorubicin and cyclophosphamide; N/A, not applicable; PSS, personal and social services.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of rituximab for the first-
line treatment of stage III/IV follicular non-
Hodgkin’s lymphoma (FNHL) based upon the 
manufacturer’s submission to the National Institute 
for Health and Clinical Excellence (NICE) as 
part of the single technology appraisal (STA) 
process. The manufacturer’s scope restricts the 
intervention to rituximab in combination with CVP 
(cyclophosphamide, vincristine and prednisolone) 
(R-CVP); the only comparator used was CVP alone. 
The evidence from the one included randomised 
controlled trial (RCT) suggests that the addition 
of rituximab to a CVP chemotherapy regimen 
has a positive effect on the outcomes of time to 
treatment failure, disease progression, overall 
tumour response, duration of response and time 
to new lymphoma treatment in patients with 
stage III/IV FNHL compared with CVP alone. 
Adverse events were comparable between the 
two arms. This study was confirmed as the only 
relevant RCT. The economic analyses provided 
by the manufacturer were modelled using a three-
state Markov model with with the health states 
being defined as progression-free survival (PFS), 
progressed (in which patients have relapsed) and 
death (which is an absorbing state). The model 
generated results for a cohort of patients with an 
initial age of 53 and makes no distinction between 
men and women. The model is basic in design, 
with several serious design flaws and key parameter 
values that are probably incompatible. Attempting 
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to rectify the identified errors and limitations of 
the model did not increase the incremental cost-
effectiveness ratio (ICER) above £30,000. Although 
the cost-effectiveness results obtained appear to 
be compelling in support of R-CVP compared 
with CVP for the trial population the results may 
not be so convincing for a more representative 
population. The results of the ERG analysis on the 
impact of age suggest that ICERs increase steadily 
with age, as the proportion of PFS that can be 
converted to overall survival (OS) is diminished by 
rising mortality rates in the general population. 
For the most extreme scenario (no OS gain) 
the ICER appears to remain below £30,000 per 
QALY gained. On balance the evidence indicates 
that R-CVP is more cost-effective than CVP. The 
guidance issued by NICE in July 2006 as a result 
of the STA states that rituximab within its licensed 
indication (in combination with cyclophosphamide, 
vincristine and prednisolone) is recommended 
as an option for the treatment of symptomatic 
stage III/IV follicular non-Hodgkin’s lymphoma in 
previously untreated patients.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of rituximab for the first-line treatment of stage III/
IV follicular non-Hodgkin’s lymphoma (FNHL).
Description of the 
underlying health problem
In the UK non-Hodgkin’s lymphoma (NHL) 
represents about 3% of all diagnosed cancers. In 
2002 the incidence of NHL was 16 per 100,000 
population and 15.6 per 100,000 population in 
England and Wales respectively. The overall rate 
of NHL is increasing by 3–4% annually. This 
is greater than expected when considering the 
ageing population and improvements in diagnosis. 
Follicular lymphoma (FL) is the second most 
common form of NHL in the UK with an incidence 
of approximately 4 per 100,000 population. It is 
considered incurable and the aim of treatment 
is to induce periods of remission, to lengthen 
remission and to improve survival and quality of 
life. There is no single accepted therapy for first-
line treatment of stage III/IV FNHL, with current 
treatment options falling into four main categories: 
alkylator-, anthracycline-, fludarabine- and R-CVP- 
(rituximab plus cyclophosphamide, vincristine and 
prednisolone)-based therapies. Guidelines from the 
British Committee for Standards in Haematology 
(BCSH)2 recommend CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisolone), an 
anthracycline-based therapy, for treatment of 
grade III FNHL, although no guidance for the 
treatment of grade IV FNHL is given. There is 
currently no consensus as to whether combination 
therapy provides additional treatment benefits 
over monotherapy. However, recent published 
clinical guidelines3 suggest that trials have shown 
advantages for combination therapy or extended 
chemotherapy with more frequent and longer 
lasting remissions and improvements to quality of 
life. 
Scope of the ERG report
The ERG report presented the results of the 
assessment of the manufacturer’s report regarding 
the use of rituximab (within the context of the 
licensed indication) in combination with CVP for 
the first-line treatment of stage III/IV FNHL.4 The 
scope of the appraisal is presented in Table 1. The 
report included an assessment of both the clinical 
and cost-effectiveness evidence submitted by the 
manufacturer (Roche) of rituximab (MabThera®), 
indicated for the treatment of previously untreated 
patients with stage III/IV FNHL in combination 
with CVP chemotherapy.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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TABLE 1  Scope of the appraisal
Clinical effectiveness Cost-effectiveness
Population Adults with stage III/IV non-Hodgkin’s lymphoma who have not received any previous 
treatment
Intervention Rituximab in combination with CVP (cyclophosphamide, vincristine and prednisolone)
Comparators CVP
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)
CNOP (cyclophosphamide, mitoxantrone, vincristine and prednisolone)
MCP (mitoxantrone, chlorambucil and prednisolone)
Chlorambucil
Outcomes Time to treatment failure Incremental cost per quality-adjusted life-year
From the draft scope: Details of the time horizon 
for the economic evaluation based on the 
time period over which costs and benefits can 
reasonably be expected given the progression of 
the disease
Tumour response (complete response, 
unconfirmed complete response, partial 
response, progressive disease)
Duration of response
Overall survival
Disease-free survival
Adverse effects of treatment
Health-related quality of life
Study design Randomised controlled trial Economic analysis
Inclusion criteria Main focus of follicular lymphoma Main focus of follicular lymphoma
Clinical trial data publications Full economic evaluation
Exclusion criteria Clinical trials in previously treated 
patients
Reviews
Animal studies or in vitro research work
No attempt to synthesis costs and benefits
Letters, editorials, commentaries or 
methodological papers
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical and cost-effectiveness of 
the technology based upon the manufacturer’s/
sponsor’s submission to NICE as part of the STA 
process. 
As part of their critical review the ERG repeated 
the searches for studies of clinical and cost-
effectiveness. An accepted tool5 relating to rigour 
of the review process and clarity of reporting was 
used to assess the methodological quality of the 
manufacturer’s literature review. The ERG assessed 
whether each paper reported in the manufacturer’s 
submission met the inclusion criteria according 
to: publication date; language; type of study 
(whether a full economic evaluation was included); 
intervention; and subjects. They conducted a 
detailed critique of the single efficacy trial included 
in the manufacturer’s submission. They critiqued 
the manufacturer’s economic model and the model 
was rerun after correcting for errors relating to 
costs and life-years gained; a Weibull survival curve 
was used to estimate survival.
In addition, because the submitted model is based 
on a cohort of patients with an unrealistically 
low average age (53 years), the ERG explored 
this further. It was observed that it was possible 
that at higher ages the apparently promising 
cost-effectiveness ratios may not be so attractive 
and could become unacceptable. It proved to be 
impossible to modify the model to allow accurate 
adjustment of age because of inherent structural 
problems and inherent inconsistencies in the model 
structures and, therefore, the ERG attempted 
a supplementary analysis. These results are 
necessarily imprecise approximations and should 
not be viewed as more than a general indication of 
the types of variations that may be expected if the 
ERG’s assumptions prove to be valid.Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
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Results 
Summary of submitted 
clinical evidence
The submitted clinical evidence includes one 
randomised controlled trial (RCT), M30921, 
comparing CVP chemotherapy alone with CVP 
in combination with rituximab and involving a 
total study population of 322 patients with stage 
III or IV FNHL. The evidence from this trial 
suggests that the addition of rituximab to a CVP 
chemotherapy regimen has a positive effect on 
the primary outcome of time to treatment failure; 
it is reported to increase from 6.6 months in 
patients receiving CVP to 27 months in patients 
in the R-CVP arm with a risk reduction of 66% 
(95% CI 55%–74%). Other positive outcomes 
were measured for disease progression, overall 
tumour response, duration of response and time 
to new lymphoma treatment. Overall survival (OS) 
was not estimable at 42 months and the 38% risk 
reduction had not reached statistical significance. 
Adverse events were comparable between the two 
arms for the proportion of patients experiencing 
at least one adverse event, although the proportion 
experiencing an adverse event in the first 24 hours 
was greater for the R-CVP arm (71% versus 51%). 
These are primarily represented by infusion-related 
events. Similar proportions of patients in each arm 
experienced grade 3–4 haematological toxicity and 
infection except for neutropenia (14.5% CVP versus 
24.1% R-CVP).
Summary of submitted cost-
effectiveness evidence
The submitted review of economic studies included 
15 studies, only eight of which actually met the 
inclusion criteria established for the review. None 
of these studies, however, compared R-CVP with 
CVP. The data extraction of the economic literature 
undertaken by the manufacturer was lacking in 
depth and no quality assessment of the included 
studies was provided. However, given the fact that 
these studies do not compare the same health-care 
technologies as the manufacturer’s own economic 
evaluation, this is of limited importance. 
The economic model included in the 
manufacturer’s submission is a three-state Markov 
model, with the health states being defined as:
•	 progression-free survival (PFS)
•	 progressed (in which patients have relapsed)
•	 death (which is an absorbing state). 
Patients begin in the PFS state and at the end of 
each cycle (cycle length 1 month) can either stay 
within this health state or move to the progressed 
health state or death state. Once in the progressed 
health state patients either move to the death state 
or continue in the progressed health state; once 
in the progressed health state they cannot return 
to PFS (Figure 1). However, the progressed state 
has been adjusted (in terms of utility) to account 
for periods of PFS. Movement between health 
states is governed by transition probabilities. The 
probabilities applied to the PFS health state vary 
over time but are generally similar between the two 
arms. The probabilities applied to the progressed 
health state are constant and do not differ between 
the two arms. The submitted model generates 
results for a cohort of patients with an initial age 
of 53 and makes no distinction between men and 
women.
Commentary on the robustness 
of submitted evidence
The single study included in the manufacturer’s 
submission was confirmed as the only relevant 
RCT. In the manufacturer’s submission the only 
comparator used was CVP alone. A wide range 
of treatment options are used in the UK for the 
treatment of FNHL, but currently there is no 
consensus on the most effective treatment. These 
include alkylator-based regimens (e.g. CVP, 
chlorambucil) or anthracycline-based regimens 
PFS
B
A
C
E
D
Progressed
Death
FIGURE 1  Structure of the Markov model (adapted from the manufacturer’s submission). PFS, progression-free survival.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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(e.g. CHOP, CNOP, MCP) used either alone or in 
combination with rituximab. Clinical guidelines, 
however, note a lack of data directly comparing 
outcomes with alternative therapeutic strategies. 
There is mention in the manufacturer’s submission 
of other studies using a variety of treatments; 
however, no analyses were carried out comparing 
the results with R-CVP. Preliminary findings of 
a meta-analysis, available only as a conference 
abstract, are discussed descriptively.
There is an issue relating to the rationale for the 
outcomes used, including an explanation of the 
reasons for using time to treatment failure as the 
primary outcome instead of OS as is usual for 
oncology clinical trials. However, although OS is a 
preferred outcome measure, in the case of FNHL 
the submission presents a persuasive rationale for 
the use of time to treatment failure.
The model submitted in support of the 
manufacturer’s submission is basic in design. It 
suffers from several serious design flaws and key 
parameter values are probably incompatible. The 
ERG attempted to rectify the identified errors and 
limitations of the model, none of which increased 
the incremental cost-effectiveness ratio (ICER) 
above the conventional threshold of £30,000. 
However, because of design flaws within the 
model as outlined in the report it was impossible 
for the ERG to simultaneously correct all of the 
errors and limitations within it. Although the 
TABLE 2  Results of analysis on impact of age on cost-effectiveness indices. Illustrative age-related model results, based on simple 
assumptions
(a)
Age
All All All All All All All
Proportion PFS gain 
is OS gain
0% 10% 20% 30% 40% 50% 60%
Incremental cost £5944 £6459 £6975 £7491 £8007 £8522 £9038
Incremental life-
years
0.000 0.190 0.381 0.571 0.762 0.952 1.143
Incremental QALYs 0.215 0.347 0.479 0.611 0.742 0.874 1.006
Incremental cost per 
life-year
N/A £33,917 £18,312 £13,111 £10,510 £8950 £7910
Incremental cost per 
QALY
£27,619 £18,615 £14,568 £12,269 £10,785 £9749 £8985
OS, overall survival; PFS, progression-free survival; QALY(s), quality-adjusted life-year(s).
(b)
Age
50 53 60 70 75
Max proportion of 
PFS gain is OS gain
67.0% 65.5% 59.4% 36.8% 12.5%
Incremental cost £9401 £9322 £9007 £7843 £6588
Incremental life-years 1.277 1.248 1.131 0.701 0.238
Incremental QALYs 1.099 1.079 0.998 0.700 0.380
Incremental cost per 
life-year
£7364 £7472 £7962 £11,185 £27,686
Incremental cost per 
QALY
£8577 £8643 £9025 £11,197 £17,343
OS, overall survival; PFS, progression-free survival; QALY(s), quality-adjusted life-year(s).Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
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cost-effectiveness results obtained appear to be 
compelling in support of R-CVP compared with 
CVP for the trial population, it could be argued 
that the results would not be so convincing for a 
more representative population.
The results of the ERG analysis on the impact of 
age (Table 2) suggest that ICERs increase steadily 
with age, as the proportion of PFS that can be 
converted to OS is diminished by rising mortality 
rates in the general population. For the most 
extreme scenario (no OS gain) the ICER appears to 
remain below £30,000 per quality-adjusted life-year 
gained.
Conclusions 
On balance the evidence indicates that R-CVP is 
more cost-effective than CVP. 
Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in July 2006 states 
that:
Rituximab within its licensed indication (that is in 
combination with cyclophosphamide, vincristine 
and prednisolone) is recommended as an option 
for the treatment of symptomatic stage III and 
IV follicular lymphoma in previously untreated 
patients.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of bortezomib 
for the treatment of multiple myeloma patients 
at first relapse and beyond, in accordance with 
the licensed indication, based upon the evidence 
submission from Ortho Biotech to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. The outcomes stated in the manufacturer’s 
definition of the decision problem were time to 
disease progression, response rate, survival and 
quality of life. The literature searches for clinical 
and cost-effectiveness studies were adequate 
and the one randomised controlled trial (RCT) 
included was of reasonable quality. Results from 
the RCT suggest that bortezomib increases survival 
and time to disease progression compared with 
high-dose dexamethasone (HDD) in multiple 
myeloma patients who have had a relapse after 
one to three treatments. Cost-effectiveness analysis 
based on the same trial and an observational study 
was reasonable and gave an estimated cost per 
life-year gained of £30,750, which ranged from 
£27,957 to £36,747 on sensitivity analysis. An 
attempt was made to replicate the results of the 
manufacturer’s model and to compare the results to 
the Kaplan–Meier survival curve presented in the 
manufacturer’s submission. In addition, a one-way 
sensitivity analysis and a probabilistic sensitivity 
analysis were undertaken, as well as additional 
scenario analyses. Based on these analyses the 
ERG suggests that the cost-effectiveness results 
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presented in the manufacturer’s submission 
may underestimate the cost per life-year gained 
for bortezomib therapy (versus high-dose 
dexamethasone) when potential UK practice and 
scenarios are considered. The guidance issued by 
NICE in June 2006 as a result of the STA states 
that bortezomib monotherapy for the treatment 
of relapsed multiple myeloma is clinically effective 
compared with HDD but has not been shown to 
be cost-effective and is not recommended for the 
treatment of progressive multiple myeloma in 
patients who have received at least one previous 
therapy and who have undergone, or are unsuitable 
for, bone marrow transplantation.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of bortezomib for the treatment of multiple 
myeloma patients.
Description of the 
underlying health problem
Multiple myeloma is a haematological cancer 
that progresses rapidly and is incurable. As well 
as reducing life expectancy it causes significant 
morbidity with painful symptoms including 
lytic bone lesions. These lead to pathological 
fractures of the long bones and vertebral collapse. 
Patients may also suffer renal failure, anaemia and 
neutropenia leading to infections. In the UK the 
median age at diagnosis is 65 years, with 1-year 
survival rates of approximately 60% and 5-year 
survival rates of approximately 25%.2,3 Multiple 
myeloma is more common in men than women3,4 
and the incidence rate among Afro-Caribbean 
populations is higher than for Caucasians of 
European descent.5
Scope of the ERG report
The ERG critically evaluated the evidence 
submission from Ortho Biotech for the use of 
bortezomib monotherapy for the treatment 
of multiple myeloma patients at first relapse 
and beyond, in accordance with the licensed 
indication.6 Bortezomib is a proteasome inhibitor 
and works by disrupting normal intracellular 
protein regulation, leading to programmed cell 
death (apoptosis).
Bortezomib was licensed for the treatment of 
people with relapsed and refractory multiple 
myeloma in 2004. The marketing authorisation 
was extended in April 2005 to allow use as a 
monotherapy for the treatment of progressive 
multiple myeloma in patients who have received at 
least one previous therapy (at first relapse) and who 
have already undergone (or who are unsuitable for) 
bone marrow transplantation.
The outcomes stated in the manufacturer’s 
definition of the decision problem were time to 
disease progression, response rate, survival and 
quality of life.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. The ERG checked the 
literature searches and applied the NICE critical 
appraisal checklist to the included studies. In 
addition, the ERG attempted to replicate the 
results of the manufacturer’s model and also 
compared the model’s results to the Kaplan–Meier 
survival curve presented in the manufacturer’s 
submission (Figure 1). A one-way sensitivity analysis 
and a probabilistic sensitivity analysis (Figure 2) 
were undertaken by the ERG, as well as additional 
scenario analyses.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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Results 
Summary of submitted 
clinical evidence
The manufacturer based the submission on one 
randomised controlled trial (RCT) comparing 
bortezomib with high-dose dexamethasone (HDD) 
in multiple myeloma patients who have had a 
relapse after one to three treatments. Results of the 
RCT suggest that bortezomib increases survival and 
time to disease progression compared with high-
dose dexamethasone in these patients.
Summary of submitted cost-
effectiveness evidence
The manufacturer submitted a cost-effectiveness 
analysis that used a decision-analytic model 
(quasi-Markov) to estimate the treatment 
effect with bortezomib compared with high-
dose dexamethasone. The model used clinical 
effectiveness data from the RCT supplemented 
with data from an observational study. Primary 
analysis presented an estimated cost per life-
year gained of £30,750. Cost per life-year gained 
ranged from £27,957 to £36,747 from sensitivity 
analyses.
Commentary on the robustness 
of submitted evidence
The literature searches for clinical and cost-
effectiveness studies were adequate and all available 
evidence was included. The RCT was of reasonable 
quality when assessed according to NICE internal 
validity criteria. However, the reporting of the trial 
lacked detail and clarity making interpretation of 
clinical effectiveness results difficult. Furthermore, 
the included RCT does not reflect current UK 
clinical practice, calling into question its external 
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validity. However, the lack of standardisation in the 
clinical management of relapsed myeloma suggests 
that the impact of this on the generalisability of 
the economic model in terms of patient group and 
comparator may be minimal. 
The manufacturer’s approach taken to model 
disease progression and cost-effectiveness in this 
patient group seemed reasonable. However, the 
manufacturer’s submission did not originally 
present quality of life issues in the economic model, 
although an additional analysis on cost per QALY 
was subsequently submitted.
The ERG considered that the economic model in 
the manufacturer’s submission may overestimate 
the treatment effect from the trial for a UK 
setting (Figure 1). Furthermore, sensitivity analyses 
undertaken in the economic evaluation were 
considered to be limited. Using what the ERG 
considered to be appropriate ranges for the 
one-way sensitivity analysis (Table 1), the most 
influential variables were the time to (disease) 
progression (TTP) hazard ratio and the cost 
of bortezomib. A sensitivity analysis was run in 
which each of the hazard ratios [TTP and overall 
survival (OS)] were varied in the same direction 
at the same time (low and high scenarios) and 
the cost-effectiveness ratios ranged from £23,287 
to £46,814. A sensitivity analysis in which the 
cost of bortezomib was varied by ±50% gave a 
cost-effectiveness ratio ranging from £18,311 to 
£43,850.
The ERG also ran an additional scenario analysis, 
which was a combination of the three scenarios run 
in the original submission (limiting the number of 
cycles of treatment from eight to three; assuming 
40% of patients were treated at first relapse, with 
the remaining 60% at second relapse and beyond; 
and using a combination of bortezomib and HDD 
as treatment). The results of the ERG scenario are 
summarised in Table 2.
The ERG probabilistic sensitivity analysis used 
the 95% confidence intervals for the hazard ratios 
and has estimated a range of ±25% for the costs. 
A cost of £470 has been used for the ‘other care 
costs’. The baseline scenario is shown in Figure 2 
with more appropriate ranges for the probabilistic 
sensitivity analysis. The results of the probabilistic 
sensitivity analysis show that the fifth percentile is 
£22,693 and the 95th percentile is £46,751 (cost 
per life-year gained). A probabilistic sensitivity 
analysis in which the cost of bortezomib varies by 
±50% had a fifth percentile of £20,364 and 95th 
percentile of £49,876.
The ERG identified that adverse events had not 
been included in the manufacturer’s model, either 
in terms of loss of quality of life or increased 
resource use.
TABLE 1  Amended one-way sensitivity analyses
Variable Base case
Inputs Cost-effectiveness ratios
Range Left Right Left Right
Hazard ratio – TTP 0.56 0.44 0.69 £25,339 £39,141 £13,802
Cost of bortezomib 
per course
£21,035 £15,776 £26,294 £24,365 £37,136 £12,770
Duration of 
treatment effect 
(years)
3 4 2 £27,957 £36,747 £8790
Cost of other 
care – bortezomib 
preprogression
£470 £352 £588 £28,266 £33,892 £5627
Hazard ratio – OS 
(year 1)
0.42 0.30 0.60 £29,317 £33,175 £3858
Cost of other 
care – pre- and 
postprogression
£470 £352 £588 £29,682 £32,476 £2795
Cost of HDD per 
course
£82 £103 £62 £30,725 £30,774 £50
HDD, high-dose dexamethasone; OS, overall survival; TTP , time to progression.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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TABLE 2  Cost-effectiveness results for additional scenario analysis
Patient group Cost per life-year gained
All patients treated at first relapse £27,334
80% of patients treated at first, 20% at second relapse £30,219
60% of patients treated at first, 30% at second, 10% at third relapse £35,783
40% of patients treated at first, 40% at second, 20% at third relapse £44,602
Note: Intervention is bortezomib plus high-dose dexamethasone (HDD) vs HDD alone; the number of cycles of treatment 
is limited in  non-responding patients; mix of patients by stage of treatment.
Conclusions 
The ERG suggests that the cost-effectiveness results 
presented in the manufacturer’s submission may 
underestimate the cost per life-year gained for 
bortezomib therapy (versus HDD) when potential 
UK practice and scenarios are considered.
There is no standard treatment for relapsed 
multiple myeloma patients, which makes assessing 
the effectiveness and cost-effectiveness of new 
treatments problematic in terms of the individuality 
of treatment protocols and which comparators to 
use. It would be useful for future trials to reflect 
current practice but this may be difficult as it is 
a quickly developing area in which clinicians are 
eager to have new treatments options for patients 
who do not easily fit into stereotypical groups.
Summary of NICE guidance 
issued as a result of the STA 
The following guidance was issued by NICE in 
October 2007:
1.1 Bortezomib monotherapy is recommended 
as an option for the treatment of progressive 
multiple myeloma in people who are at first 
relapse having received one prior therapy 
and who have undergone, or are unsuitable 
for, bone marrow transplantation, under the 
following circumstances:
  – the response to bortezomib is measured 
using serum M protein after a maximum 
of four cycles of treatment, and treatment 
is continued only in people who have 
a complete or partial response (that is, 
reduction in serum M protein of 50% or 
more or, where serum M protein is not 
measurable, an appropriate alternative 
biochemical measure of response) and 
  – the manufacturer rebates the full cost 
of bortezomib for people who, after a 
maximum of four cycles of treatment, have 
less than a partial response (as defined 
above).
1.2 People currently receiving bortezomib 
monotherapy who do not meet the criteria 
in paragraph 1.1 should have the option to 
continue therapy until they and their clinicians 
consider it appropriate to stop.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of fludarabine phosphate or 
fludarabine plus cyclophosphamide for the first-
line treatment of chronic lymphocytic leukaemia, 
based upon the evidence submission from Schering 
Health Care (SHC) to the National Institute for 
Health and Clinical Excellence (NICE) as part 
of the single technology appraisal (STA) process. 
The submission was of good quality with no 
major errors or omissions in the clinical evidence. 
Two published studies and seven abstracts were 
included in the company submission, which 
showed improvements in overall response and 
progression-free survival (PFS) and a higher 
complete response rate in the fludarabine-
containing arms; however, until the complete data 
are made available for evaluation these results must 
be interpreted with caution. The manufacturer’s 
decision-analytic Markov model to estimate the 
cost-effectiveness of treatment with fludarabine 
monotherapy, fludarabine plus cyclophosphamide 
and chlorambucil was considered to be the 
most relevant source for informing this STA; 
it was appropriate for the decision problem 
and the data sources used to inform the model 
were appropriate from a UK NHS perspective. 
The incremental cost-effectiveness ratio of 
fludarabine plus cyclophosphamide compared 
with chlorambucil from the revised model 
presented in the manufacturer’s addendum was 
£3244 per additional quality-adjusted life-year. 
The results were robust to a range of subgroup 
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and sensitivity analyses. Additional sensitivity 
and survival analyses were carried by the ERG to 
investigate possible bias in the results. This brought 
into question the validity of the assumptions 
underpinning the extrapolation of data over a 
lifetime time horizon and showed that the ICER 
estimates submitted by the manufacturer were not 
calculated correctly and uncertainty surrounding 
the decision problems was not expressed fully. 
Based on these analyses the ERG suggests that 
further evidence is needed to enable an accurate 
assessment to be made of the clinical and cost-
effectiveness of fludarabine as first-line treatment 
for chronic lymphocytic leukaemia. The guidance 
issued by NICE in December 2006 as a result of 
the STA states that fludarabine monotherapy, 
within its licensed indication, is not recommended 
for the first-line treatment of chronic lymphocytic 
leukaemia; no recommendations have been made 
with respect to fludarabine plus cyclophosphamide 
combination therapy because the current 
marketing authorisation does not specifically 
provide a recommendation that fludarabine should 
be used concurrently with other drugs for the 
treatment of chronic lymphocytic leukaemia.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of fludarabine phosphate for the first-line 
treatment of chronic lymphocytic leukaemia.2
Description of the 
underlying health problem
Chronic lymphocytic leukaemia (CLL) is defined as 
a slow progressive form of leukaemia characterised 
by an increased number of lymphocytes,3 mostly 
of small or medium size, with clumped nuclear 
material (chromatin), an indistinct or absent 
nucleoli and little cytoplasm.4 The other type of 
lymphocyte commonly observed in approximately 
15% of patients is a prolymphocyte, which appears 
large with a prominent nucleolus.4,5 The general 
symptoms of CLL are tiredness, night sweats, 
weight loss, anaemia and associated symptoms, 
and increased susceptibility to infection.4 The 
lymphocytes may also accumulate in the lymph 
nodes and spleen resulting in lymphadenopathy, 
splenomegaly and other abdominal masses.4,5 
Frequently the condition is identified by chance 
during a routine blood test in the absence of 
specific symptoms or physical signs. At the point of 
diagnosis CLL is usually widespread and with some 
degree of bone marrow involvement. With the 
exception of blood and marrow transplantation, 
the condition is inherently incurable with treatment 
emphasis on maintaining an acceptable state of 
health and inducing remission when required.5 
B-cell CLL is reported to be the most common 
leukaemia, representing approximately 25% of all 
cases of leukaemia.6 In England and Wales in 2003 
there were 6198 cases of leukaemia;7,8 assuming 
that 25% of these are B-cell CLL means that there 
were approximately 1550 new cases of B-cell 
CLL diagnosed in 2003. This indicates a crude 
incidence in this population of approximately 3 
per 100,000 population per year;7–9 however, this 
belies the demographics of its incidence. CLL 
is rare below the age of 30 years with 20–30% of 
patients presenting under the age of 55 years.4 The 
peak incidence is between 60 and 80 years, with the 
incidence increasing up to almost 50 per 100,000 
population per year after the age of 70 years.6 It is 
male dominant, occurring with a male–female ratio 
of 2:1.4,10
Scope of the ERG report
The report critically evaluates the evidence 
submission from Schering Health Care (SHC) on 
the clinical and cost-effectiveness of fludarabine 
phosphate (Fludara®) or fludarabine plus 
cyclophosphamide for the first-line treatment of 
chronic lymphocytic leukaemia.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG undertook additional work to examine 
the potential robustness of the base-case results 
to several of the assumptions made in the 
manufacturer’s model and also to identify possible 
sources of bias. This work was performed on the 
revised model presented in the manufacturer’s 
addendum and was separated into three main 
areas: (1) additional one-way sensitivity analyses 
to examine the robustness of the base-case 
incremental cost-effectiveness ratio (ICER) to 
alternative assumptions related to the response 
rate for retreatment and the duration of this 
response; (2) a more appropriate presentation of 
the probabilistic sensitivity analysis results from 
the submission; and (3) formal survival analysis of 
the individual patient data from the CLL4 trial to 
explore the appropriateness of assuming constant 
transition probabilities to extrapolate over a 
lifetime time horizon. These were selective analyses 
and the revised economic analyses were undertaken 
to examine the robustness of the manufacturer’s 
own model to alternative assumptions. These 
analyses were thus subject to potential limitations 
regarding the structural assumptions, the general 
approach used to estimate transition probabilities 
and issues related to the modelling of second-line 
treatments. The results should, therefore, be taken 
as indicative of the potential impact on the cost-
effectiveness estimates.
Results
Summary of submitted 
clinical evidence
Two published studies11,12 and seven abstracts 
were included in the company submission. 
Fludarabine or fludarabine plus cyclophosphamide 
were compared with chlorambucil (Chl) 
in five studies12–16 and two studies11,17 
compared fludarabine with fludarabine plus 
cyclophosphamide. Only one study compared all 
three regimens.13,18
All studies, with one exception,16 showed an 
improvement in overall response (OR) in those 
patients receiving fludarabine compared with 
those receiving Chl.11–15,17 In all but one15 of the 
studies comparing fludarabine or fludarabine plus 
cyclophosphamide with Chl there was a higher 
complete response (CR) rate for the fludarabine-
containing arms.12–14,16 Although progression-free 
survival (PFS) was stated as a primary outcome 
measure in five studies,11–14,17 this outcome was 
fully reported in only three.11,12,17 In one study 
comparing differences in median PFS between 
the fludarabine and Chl regimens there was a 
significantly longer duration of response in the 
fludarabine arm.12 Two studies demonstrated a 
significantly longer duration of response with the 
fludarabine plus cyclophosphamide combination 
compared with fludarabine alone.11,17 At present, 
the follow-up periods of the studies included 
in the submission are too short to demonstrate 
any significant improvement in overall survival 
(OS). Therefore, fully matured survival data are 
necessary to ascertain whether any improvement 
in PFS translates into an increase in OS. Three 
studies included quality of life (QoL) analyses; 
however, only limited data from the CLL4 study 
are presented.18 In this study QoL was the same 
for each treatment group at baseline and at 12 
months and correlated with the quality of response. 
It is anticipated that the results of further QoL 
analyses are likely to become available within the 
next year. Because five of the studies included 
in the submission are not fully published and 
report only preliminary results in abstract form 
there are insufficient data presented to fully assess 
the validity of these studies.13–16 Although the 
unpublished CLL4 study13 is supplemented with 
additional patient-level data18 provided by the 
manufacturer to support the health economic 
analyses, these supplemental data are not in the 
public domain and therefore cannot be verified 
externally. Until these studies are fully published 
and the complete data made available for 
evaluation, these results must be interpreted with 
caution.
Summary of submitted cost-
effectiveness evidence
Two papers were identified in both the 
manufacturer’s submission and the ERG searches 
that reported on the cost-effectiveness of 
fludarabine monotherapy compared with Chl in 
the management of CLL in previously untreated 
patients.19,20 Neither of the studies was considered 
particularly relevant because of the limited 
clinical and economic evidence on which the 
studies were based (mainly because of the limited 
evidence available at the time that these studies 
were undertaken) and the restricted range of 
comparators considered. Neither of these studies 
considered the cost-effectiveness of fludarabine Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
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combined with cyclophosphamide as a first-line 
treatment for CLL. Consequently, the submission 
by the manufacturer was considered to comprise 
the most relevant evidence for the purposes of this 
STA. 
The manufacturer’s submission included a de novo 
decision-analytic Markov model to estimate the 
cost-effectiveness of treatment with (1) fludarabine 
monotherapy, (2) fludarabine in combination with 
cyclophosphamide and (3) Chl. The model used 
individual patient data from the CLL4 trial to 
model transition probabilities related to first-line 
treatment with these therapies. The costs of first-
line treatment were derived from an audit of UK 
patients from the CLL4 trial. The model was based 
on a lifetime time horizon and included the costs 
and consequences of further treatments required 
after first-line treatment had failed. Data on the 
costs and effects of further treatment (including 
retreatment and second-line and salvage therapies) 
were derived from a combination of secondary 
sources and assumptions by the manufacturer. 
Results were presented in terms of the incremental 
cost per quality-adjusted life-year (QALY) gained, 
with QoL estimates informed by a separate 
systematic review. In the original submission 
by the manufacturer, the incremental cost-
effectiveness (ICER) of fludarabine in combination 
with cyclophosphamide compared with Chl was 
£2602 per additional QALY. Fludarabine in 
combination with cyclophosphamide was reported 
to dominate fludarabine (i.e. was less costly and 
more effective). These results were based on an 
approach which assumed that median (as opposed 
to mean) survival was equal in all treatments. An 
addendum was submitted by the manufacturer, 
which presented similar results based on an 
approach that equalised mean survival. This 
latter approach was considered by the ERG to 
be a more appropriate assumption. The results 
presented in the addendum increased the ICER of 
fludarabine in combination with cyclophosphamide 
compared with Chl to £3244 per additional QALY. 
Fludarabine plus cyclophosphamide continued to 
dominate fludarabine. The results of the subgroup 
analysis presented by age and Binet stage did 
not substantially alter these results. Similarly, 
the results were reported to be robust to a wide 
range of sensitivity analyses undertaken by the 
manufacturer. The results were most sensitive to the 
time horizon of the model, such that fludarabine 
plus cyclophosphamide did not appear cost-
effective at a time horizon of 5 years.
Commentary on the robustness 
of submitted evidence
Strengths 
The ERG felt that the SHC submission was 
generally of good quality. There were no major 
errors or omissions in the clinical evidence. The 
majority of the data quoted within the submission 
was a fair and accurate representation of the 
original reference data. The ERG noted the 
limitations of existing cost-effectiveness studies 
in this area and considered the economic model 
submitted by the manufacturer to be the most 
relevant source for the purpose of informing this 
STA. The economic model structure (including 
the comparators) was considered appropriate for 
the decision problem, and the data sources used to 
inform the model were deemed appropriate from 
a UK NHS perspective. A range of subgroups was 
considered and uncertainty in parameter estimates 
was addressed using probabilistic approaches. 
Weaknesses 
The majority of the reference data presented 
in the submission was not fully published and 
was only available in abstract form. Therefore, 
the ERG felt that, until these studies are fully 
published and the complete data made available 
for evaluation, these results must be interpreted 
with caution. The ERG identified a number of 
potential sources of weakness in the manufacturer’s 
economic submission. In particular, a number of 
issues were identified that may have introduced 
possible bias into the results. Most of these issues 
appeared to act in favour of the fludarabine 
plus cyclophosphamide regimen such that it is 
likely that the manufacturer’s results are overly 
optimistic towards this regimen. The robustness of 
the manufacturer’s results to some of these issues 
was explored in additional work undertaken by 
the ERG. The cost-effectiveness of fludarabine in 
combination with cyclophosphamide appeared 
relatively robust to wide variation in several of the 
key assumptions made by the manufacturer. The 
ERG was concerned with the approach that the 
manufacturer used to estimate a number of key 
probabilities derived from the CLL4 trial data. 
Because of the structure of the model it was not 
possible to fully explore the potential robustness 
of the manufacturer’s results to alternative 
assumptions. However, work undertaken by the 
ERG brought into question the validity of the 
assumptions underpinning the extrapolation of 
data over a lifetime time horizon. In addition, the 
ERG noted that the ICER estimates submitted by 
the manufacturer were not calculated correctly and Health Technology Assessment 2009; Vol. 13: Suppl. 1
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uncertainty surrounding the decision problems 
was not expressed fully. The revised ICER results 
are presented in Table 1, with the associated cost-
effectiveness acceptability curves given in Figure 1. 
Areas of uncertainty 
The fludarabine summary of product characteristics 
(SPC) does not mention the use of fludarabine in 
combination with other chemotherapeutic agents. 
The dose for oral therapy in combination with 
cyclophosphamide does not appear to be a licensed 
dose and is not mentioned in the SPC. The SPC 
for cyclophosphamide states that it is frequently 
used in combination chemotherapy regimens 
involving other cytotoxic drugs and that it is 
recommended that the calculated dose be reduced 
at the discretion of the clinician when it is given 
in combination with other antineoplastic agents 
or radiotherapy and in patients with bone marrow 
suppression. However, the ERG feels that the 
efficacy of the fludarabine plus cyclophosphamide 
regimen is still under investigation and that 
the recommendations outlined in the British 
Committee for Standards in Haematology (BCSH) 
guidelines are expected to be revised following 
the outcomes of the CLL4 study. Therefore, the 
ERG sought clarification on this matter from the 
manufacturer. The manufacturer believes that 
the proposed regimen falls within the current 
licenses and states that they are not, therefore, 
considering an extension to the fludarabine license. 
The dosing 11 regimen for the fludarabine plus 
cyclophosphamide combination was agreed by 
expert clinicians within the MRC/LRF UK-CLL 
group. However, independent expert advice given 
to the ERG confirms that the fludarabine plus 
cyclophosphamide regimen is increasingly used for 
the first-line treatment of CLL and that the dosing 
regimen chosen also reflects current practice. 
Conclusions 
To enable an accurate assessment to be made of 
the clinical and cost-effectiveness of fludarabine 
as first-line treatment for chronic lymphocytic 
leukaemia there is a need for further evidence to 
clarify areas of uncertainty.
TABLE 1  Probabilistic sensitivity analysis results
Comparator Mean costs Mean QALYs
ICER 
(compared 
with Chl)
Probability cost-effective at willingness to pay
£20,000 £30,000 £40,000
Chl £11,836 5.48 – 0.047 0.032 0.028
F £17,840 5.70 Dominated 
by FC
0.04 0.067 0.09
FC £13,291 6.13 £3213 0.913 0.901 0.882
Chl, chlorambucil; F, fludarabine; FC, fludarabine with cyclophosphamide; ICER, incremental cost-effectiveness ratio; QALYs, 
quality-adjusted life-years.
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FIGURE 1  Cost-effectiveness acceptability curves – revised by the ERG. QALY, quality-adjusted life-year; WTP , willingness to pay.Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
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Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in December 2006 
states that:
Fludarabine monotherapy, within its licensed 
indication, is not recommended for the first-line 
treatment of chronic lymphocytic leukaemia. No 
recommendations have been made with respect to 
fludarabine plus cyclophosphamide combination 
therapy because the current marketing 
authorisation does not specifically provide a 
recommendation that fludarabine should be used 
concurrently with other drugs for the treatment of 
chronic lymphocytic leukaemia.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of erlotinib for the treatment 
of relapsed non-small cell lung cancer (NSCLC), 
according to its licensed indication, based upon 
the evidence submission from Roche Products 
to the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The submitted clinical 
evidence includes one randomised controlled trial 
(RCT) (BR21) investigating the effect of erlotinib 
versus placebo, which demonstrates that erlotinib 
significantly increases median overall survival, 
progression-free survival and response rate 
compared with placebo. The majority of patients 
in the trial experienced non-haematological 
drug-related adverse effects. Currently there 
are no trials that directly compare erlotinib with 
any other second-line chemotherapy agent. 
For the purposes of indirect comparison, the 
manufacturer’s submission provides a narrative 
discussion of data from 11 RCTs investigating the 
use of docetaxel. From these data the manufacturer 
concludes that erlotinib has similar clinical 
efficacy levels to docetaxel but results in fewer 
serious haematological adverse events; however, 
it is difficult to compare the results of BR21 with 
those of the docetaxel trials or with current UK 
clinical practice because, for example, the BR21 
patient population is younger than that expected 
to present in UK clinical practice and almost half 
of the BR21 participants received erlotinib as third-
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line chemotherapy, with third-line chemotherapy 
being rare in the UK. The manufacturer’s 
submission included a three-state model 
comparing erlotinib with docetaxel, reporting 
an incremental cost-effectiveness ratio (ICER) 
of –£1764 per quality-adjusted life-year (QALY) 
gained for erlotinib compared with docetaxel. 
Rerunning the manufacturer’s economic model 
with varied parameters and assumptions increases 
the ICER to in excess of £52,000 per QALY gained. 
There is still a large amount of unquantifiable 
uncertainty in the model and it is unlikely that 
erlotinib could be considered to be cost-effective 
compared with docetaxel at a willingness to pay of 
£30,000 and there may even be the potential for 
docetaxel to dominate erlotinib. Because of the 
limitations of the indirect analysis undertaken by 
the manufacturer and the subsequent economic 
modelling exercise there is a need for a head-to-
head trial comparing erlotinib with docetaxel. 
The guidance issued by NICE in February 2007 
as a result of the STA states that erlotinib is 
not recommended for the treatment of locally 
advanced or metastatic NSCLC.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of erlotinib for the treatment of relapsed non-small 
cell lung cancer (NSCLC).2
Description of the 
underlying health problem
Lung cancer is the most common cause of cancer-
related death in men and the second most common 
cause of cancer-related death after breast cancer 
in women.3
 
In 2002, 37,700 patients were newly 
diagnosed with lung cancer in the UK, accounting 
for one in seven new cancer cases, with an 
incidence of about 62–65 per 100,000 population; 
the incidence of NSCLC is approximately 52 
per 100,000 population.4 Lung cancer is rarely 
diagnosed in people under 40 years of age, but the 
incidence rises steeply with age thereafter, peaking 
in people aged 75–84 years.4
 
The male–female 
ratio for lung cancer cases is 3:2.4
 
There is a strong 
association between incidence and mortality rates 
and levels of deprivation.4
Scope of the ERG report
The ERG report presents the results of the 
assessment of the manufacturer’s (Roche Products) 
evidence submission regarding the use of erlotinib 
for the second-line treatment of patients with 
locally advanced or metastatic (stage III/IV) 
NSCLC. The report includes an assessment of 
both the clinical and cost-effectiveness evidence 
submitted by the manufacturer. Erlotinib (Tarceva®) 
is an orally active inhibitor of epidermal growth 
factor receptor/human epidermal growth factor 
receptor 1 (EGFR/HER1) tyrosine kinase inhibitor. 
In 2004, pemetrexed (Alimta®; Lilly) received a 
licence for use ‘as monotherapy for the treatment 
of patients with locally advanced or metastatic non-
small cell lung cancer after prior chemotherapy’. 
The licensing submission for pemetrexed was 
supported by a phase III study comparing 
pemetrexed and docetaxel.5 In 2005, erlotinib was 
licensed ‘for the treatment of patients with locally 
advanced or metastatic non-small cell lung cancer 
after failure of at least one prior chemotherapy 
regimen’. The licensing submission for erlotinib 
was supported by a phase III study comparing 
erlotinib with placebo.6
Methods 
The ERG report comprised a critical review of 
the evidence for the clinical effectiveness and 
cost-effectiveness of the technology based upon 
the manufacturer’s/sponsor’s submission to NICE Health Technology Assessment 2009; Vol. 13: Suppl. 1
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as part of the STA process. The ERG assessed 
the quality of the clinical effectiveness review 
using a checklist and conducted a literature 
search. The group fitted exponential curves 
to the manufacturer’s Kaplan–Meier plots to 
calculate overall survival (OS) and also reran the 
manufacturer’s economic model after correcting 
for an inherent error and altered some of the 
assumptions and parameter values to recalculate 
the cost–utility ratios, quality-adjusted life-years 
(QALYs) and estimates of benefits. 
Results
Summary of submitted 
clinical evidence
The submitted clinical evidence includes one 
randomised, placebo-controlled, double-blind trial 
(BR21)6
 
that investigates the effect of erlotinib 
within its licensed indication (treatment of 
relapsed NSCLC) versus placebo. The BR21 trial 
demonstrates that erlotinib significantly increases 
median OS by 42.5% compared with placebo (6.7 
months versus 4.7 months respectively; p < 0.001, 
hazard ratio 0.70). Progression-free survival (PFS) is 
significantly longer in the erlotinib arm compared 
with the placebo arm (2.2 months versus 1.8 
months respectively; p < 0.001, hazard ratio 0.61) 
and the overall response rate is significantly higher 
(8.9% versus 0.9%; p < 0.001). 
The majority of patients in the BR21 trial 
experienced non-haematological drug-related 
adverse effects (AEs). The most commonly reported 
AEs attributed to erlotinib were rash (76%) and 
diarrhoea (55%), leading to a dose reduction in 
12% and 5% of patients respectively. Currently 
there are no trials that directly compare erlotinib 
with any other second-line chemotherapy agent. 
For the purposes of indirect comparison, the 
manufacturer’s submission provides a narrative 
discussion of data from 11 randomised controlled 
trials (RCTs) investigating the use of docetaxel at 
a dose of 75 mg/m2. The manufacturer extracted 
detailed data from two of the 11 trials involving 
docetaxel: docetaxel versus best supportive care 
(TAX317)7 and docetaxel versus pemetrexed 
(JMEI)5. In these trials docetaxel showed similar 
efficacy levels to those of erlotinib as reported 
in the BR21 trial. Median OS was 7.5 months 
(docetaxel, TAX317), 7.9 months (docetaxel, JMEI) 
and 6.7 months (erlotinib, BR21). Median PFS was 
reported as 2.9 months (docetaxel, JMEI) and 2.2 
months (erlotinib, BR21) and overall response rates 
were reported as 8.9% (docetaxel, JMEI) and 8.8% 
(erlotinib, BR21). Analyses of TAX317 and JMEI in 
relation to the BR21 study demonstrated the lower 
rates of haematological toxicities experienced 
by patients receiving erlotinib compared with 
those receiving docetaxel, particularly incidences 
of febrile neutropenia. The manufacturer’s 
submission therefore concludes that erlotinib has 
similar clinical efficacy levels to docetaxel but 
results in fewer serious haematological adverse 
events. When interpreting the results of BR21 a 
number of issues relating to the patient population 
must be considered. For example, the BR21 
patient population is younger than that expected 
to present in UK clinical practice. Almost half of 
the trial participants received erlotinib as third-
line chemotherapy, with third-line chemotherapy 
being rare in the UK. Furthermore, a large number 
of participants in the BR21 trial had an Eastern 
Cooperative Oncology Group performance status 
(ECOG PS) of 2–3; typically patients receiving 
chemotherapy in UK clinical practice have a PS of 
0–1. For these reasons it is difficult to compare the 
results of BR21 with those of TAX317 and JMEI or 
with current UK clinical practice.
Summary of submitted cost-
effectiveness evidence
The economic model submitted in support of 
the manufacturer’s submission is a basic three-
state model comparing erlotinib with docetaxel, 
furnished with clinical data from the TAX317 
and BR21 trials. The manufacturer reports an 
incremental cost-effectiveness ratio (ICER) of 
–£2941 per QALY for erlotinib compared with 
docetaxel, with a 68% probability that erlotinib 
is cost-effective at a willingness to pay (WTP) of 
£30,000 per QALY gained. After adjustment for 
the double counting of half-cycle correction, the 
manufacturer’s model yields a corrected ICER of 
–£1764. However, a number of key assumptions 
and parameters in the model do not seem to be 
clinically and/or economically justified, particularly 
in terms of costs. For example, the manufacturer 
underestimates the acquisition cost of erlotinib 
and overestimates the acquisition cost of docetaxel. 
Once these assumptions are adjusted to reflect 
more realistic estimates, the ICER increases to 
£52,098 per QALY as shown in Table 1, with a 44% 
probability that erlotinib is cost effective at a WTP 
of £30,000. A modified cost-acceptability curve 
using manufacturer probabilistic sensitivity analysis 
(PSA) results adjusted for average incremental 
cost and outcome alterations and a modified 
cost-effectiveness uncertainty scatter plot using 
manufacturer PSA results adjusted for average 
incremental cost and outcome alterations are 
shown in Figures 1 and 2 respectively.Erlotinib for the treatment of relapsed non-small cell lung cancer
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TABLE 1  Cost-effectiveness summary table updated for identified corrections and amendments to the manufacturer’s model
Erlotinib Docetaxel Increment
Costs per patient
Drug acquisition £7164 £5022 £2142
Drug administration and monitoring £473 £839 –£365
Adverse event treatment £113 £374 –£261
Other preprogression care £1034 £859 £175
Postprogression care £4699 £5444 –£745
Total cost £13,482 £12,536 £946
Outcomes per patient
Overall mean survival (months) 9.03 9.03 0.00
PFS (months) 4.11 3.33 0.78
PPS (months) 4.92 5.70 –0.78
PFS QALYs 0.1591 0.1139 0.0452
PPS QALYs 0.0953 0.1224 –0.0271
Total QALYs 0.2544 0.2362 0.0182
Incremental cost per QALY £52,098
PFS, progression-free survival; PPS, post-progression survival; QALY(s), quality-adjusted life-year(s).
In terms of health outcomes a further issue is the 
use of visual analogue scale (VAS) scores from 
the Oxford Outcomes study; the scores were not 
adjusted to zero for death and conflict with the 
tariff values calculated using responses from the 
same sample of healthy volunteers. As presented 
in Table 2, reanalysis of the model rescaling the 
VAS PFS utility scores to ensure that death has 
zero utility further increased the ICER (£68,673 
per QALY gained). Similarly, reanalysis using tariff 
PFS utility values led to an ICER slightly above 
the WTP threshold of £30,000 (£31,261 per QALY 
gained). Joint exploration of uncertainty in the cost 
of docetaxel and the degree of variation in dosing 
introduced by clinical judgement yields a range of 
ICER estimates between £41,943 and £70,418 per 
QALY gained. 
There is also a large amount of unquantifiable 
uncertainty in the model relating to AEs, 
postprogression survival and PFS health state costs, 
and the length of PFS. These areas of ambiguity 
FIGURE 1  Modified cost-effectiveness curve using manufacturer probabilistic sensitivity analyses results adjusted for average 
incremental cost and outcome alterations. WTP , willingness to pay.Health Technology Assessment 2009; Vol. 13: Suppl. 1
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
45
0.5
–8
10
8
6
4
0
–4
–0.5 –0.4 0
£30,000 per QALY gained
–0.2
Incremental QALYs per patient
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
 
p
e
r
 
p
a
t
i
e
n
t
 
(
£
0
0
0
)
0.2 0.4 –0.3 0.1 –0.1 0.3
2
–2
–6
FIGURE 2  Modified cost-effectiveness uncertainty scatter plot using manufacturer probabilistic sensitivity analyses results adjusted for 
average incremental cost and outcome alterations. QALY(s), quality-adjusted life-year(s).
could potentially further increase the ICER and 
may even result in docetaxel dominating erlotinib.
Commentary on the robustness 
of submitted evidence
A major limitation in the manufacturer’s 
submission is the reliance on the BR21 trial 
(currently the only available erlotinib study) 
which compares erlotinib with placebo, rather 
than an accepted chemotherapy regimen. As 
a consequence, the manufacturer’s submission 
is forced to compare erlotinib and docetaxel 
indirectly; such comparisons have inherent 
difficulties and are subject to biases.
Further to this, there are a number of differences 
between the patient population in the BR21 
trial and the TAX317 study, of which the most 
important are the number of prior chemotherapy 
regimens and the performance status of patients.
TABLE 2  Sensitivity analyses – alternative methods to estimate utility in preprogression period
Erlotinib Docetaxel Increment
Using rescaled VAS values in PFS
PFS QALYs (rescaled VAS) 0.1292 0.0883  0.0409
PPS QALYs (the ERG estimate) 0.0953 0.1224 –0.0271
Total QALYs 0.2245 0.2107  0.0138
Incremental cost per QALY £68,673
Using tariff values in PFS
PFS QALYs (tariff) 0.1337 0.0763 0.0573
PPS QALYs (the ERG estimate) 0.0953 0.1224 –0.0271
Total QALYs 0.2289 0.1987 0.0303
Incremental cost per QALY £31,261
ERG, evidence review group; PFS, progression-free survival; PPS, post-progression survival; QALY(s), quality-adjusted life-
year(s); VAS, visual analogue scale.Erlotinib for the treatment of relapsed non-small cell lung cancer
46
TABLE 3  Main elements of monthly postprogression costs per patient
Component Cost per month Proportion
Hospital episodes £547.97 55.4%
Health professionals £331.54 33.5%
Medications £39.46 4.0%
Tests £69.83 7.1%
Total £988.80 100.0%
In addition, the best supportive care component 
of treatment may not be comparable between the 
trials, which could potentially inflate a treatment 
response in one of the trials unjustifiably. This 
confounding issue was not discussed in the 
manufacturer’s submission, but should have been 
considered when the indirect comparison was 
undertaken.
A number of unquantifiable areas of uncertainty 
were found and relate to AEs, pre- and post-
progression health state costs and progression-free 
survival. There is a note in the manufacturer’s 
table of event probabilities for AEs, which seems 
to imply that the model does not allow patients 
to suffer multiple adverse events. If this is so it is 
a severe and unrealistic constraint, as individual 
patients frequently suffer multiple events either 
concurrently (e.g. rash with diarrhoea) or serially. 
In addition, the resources assumed to be incurred 
each month for patients before and after disease 
progression were exclusively determined by five 
clinical experts without use of any observational 
data. The main elements contributing to the 
increase in such costs postprogression are shown 
in Table 3. Clearly hospital episodes constitute the 
dominant component in these estimates. It seems 
disappointing that no attempt has been made to 
sample routine hospital records and statistics to 
validate the expert opinion in this respect. The 
ERG raised issues about the validity of the claims 
of equivalence in overall survival and of improved 
PFS with erlotinib. These are of profound 
importance to the economic evaluation of erlotinib 
as if either of these assertions proves to be 
untenable then most of the modest outcome gains 
claimed for erlotinib will disappear, other than 
the very small short-term quality of life benefits 
associated with oral administration and reduced 
AEs. In the context of important increases in drug 
acquisition costs this would mean that erlotinib 
could not be considered cost-effective and might 
in fact be dominated by docetaxel (more expensive 
and less effective).
Conclusions
The manufacturer’s submission presents a case 
for the replacement of docetaxel by erlotinib as 
second-line chemotherapy for NSCLC patients 
with advanced or metastatic disease. However, 
there is a proportion of NSCLC patients whose 
poor health status precludes them from receiving 
docetaxel; for these patients best supportive care 
is currently the only treatment option available. It 
may be argued that some of these patients could be 
considered for erlotinib instead of docetaxel as it is 
a less demanding oral regimen. 
The ERG attempted to rectify several of the 
limitations in the clinical and cost-effectiveness 
evidence submitted, generating much higher 
incremental cost-effectiveness ratios than those 
generated in the manufacturer’s submission 
(in excess of £52,000). This extreme sensitivity 
is due to the very small value of incremental 
benefit, which renders the ICER highly unstable 
to small changes. There is still a large amount 
of unquantifiable uncertainty, however at the 
current price it is unlikely that erlotinib could 
be considered to be cost effective compared with 
docetaxel at a WTP of £30,000. There may even be 
the potential for docetaxel to dominate erlotinib 
(i.e. be more effective yet less expensive). This 
means that adoption of erlotinib would need to be 
justified on grounds out with the factors included 
in the model (for example, patient preference 
for oral self-medication and service pressures to 
limit or reduce demand for hospital administered 
chemotherapy). 
Given the limitations of the indirect analysis 
undertaken by the manufacturer and the 
subsequent economic modelling exercise there is a 
need for a head-to-head trial comparing erlotinib 
with docetaxel.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in February 2007 
states that: 
1.1 Erlotinib is recommended, within its 
licensed indication, as an alternative to 
docetaxel as a second-line treatment option 
for patients with non-small-cell lung cancer 
(NSCLC) only on the basis that it is provided 
by the manufacturer at an overall treatment 
cost (including administration, adverse 
events and monitoring costs) equal to that of 
docetaxel.
1.2 The decision to use erlotinib or docetaxel 
(as outlined in section 1.1) should be made 
after a discussion between the responsible 
clinician and the individual about the potential 
benefits and adverse effects of each treatment.
1.3 Erlotinib is not recommended for the 
second-line treatment of locally advanced 
or metastatic NSCLC in patients for whom 
docetaxel is unsuitable (that is, where there 
is intolerance of or contraindications to 
docetaxel) or for third-line treatment after 
docetaxel therapy.
1.4 People currently receiving treatment with 
erlotinib, but for whom treatment would not 
be recommended according to section 1.3, 
should have the option to continue treatment 
until they and their clinicians consider it 
appropriate to stop.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of cetuximab plus radiotherapy 
for the treatment of locally advanced squamous 
cell carcinoma of the head and neck (LA SCCHN) 
considered inappropriate for chemoradiotherapy 
but appropriate for radiotherapy, based upon the 
evidence submission from Merck Pharmaceuticals 
to the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The manufacturer’s 
submission was generally of good quality and was 
an accurate representation of the original reference 
data. One good-quality randomised controlled 
trial comparing radiotherapy plus cetuximab 
with radiotherapy alone in patients with stage III 
or IV non-metastatic LA SCCHN was included, 
demonstrating that the duration of locoregional 
control was significantly longer with radiotherapy 
plus cetuximab than with radiotherapy alone; 
also, overall and progression-free survival were 
significantly longer and the overall response rate 
was significantly better with the combination 
therapy. Cetuximab did not exacerbate the 
common toxic effects associated with radiotherapy 
of the head and neck. No supporting evidence 
for these findings are available. The patient 
population in the trial included a high proportion 
of patients who would be expected to be suitable 
for chemoradiotherapy and therefore does not 
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match the population described in the submission’s 
decision problem. Also, the radiotherapy regimens 
used in the trial are not typical of current UK 
practice. The ERG considered the manufacturer’s 
economic evaluation to comprise the only relevant 
evidence to consider for the purposes of this STA. 
The economic model was considered appropriate 
for the decision problem. The results suggested 
that cetuximab plus radiotherapy was cost-effective 
compared with radiotherapy alone under a broad 
range of different assumptions on the basis of a 
cost-effectiveness threshold of £20,000. In the 
base case the incremental cost-effectiveness ratio 
of cetuximab plus radiotherapy compared with 
radiotherapy alone in the treatment of patients 
with LA SCCHN was £6390 per additional 
QALY. Simple sensitivity analyses to examine 
the robustness of the results were undertaken, 
suggesting that areas of uncertainty that emerged 
in the modelling are unlikely to have a material 
effect on the conclusions. The guidance issued by 
NICE in May 2007 as a result of the STA states that 
cetuximab in combination with radiotherapy is not 
recommended for patients with LA SCCHN. 
Introduction 
The National Institute of Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of cetuximab plus radiotherapy for the treatment 
of locally advanced squamous cell carcinoma of the 
head and neck (LA SCCHN).2
Description of the 
underlying health problem
Head and neck cancer is a broad term for any 
cancer from the base of the neck upwards,3 
excluding tumours of the brain and related 
tissues and malignant melanomas.4,5 The most 
common histological type of head and neck 
cancer is a squamous cell carcinoma, particularly 
affecting the oral cavity and larynx, although 
patients may present with more than one primary 
cancer.3,5,6 In 2003 there were over 5000 new 
cases of cancer of the oral cavity, oropharynx, 
hypopharynx and larynx in England. Male 
prevalence dominates (70%), possibly because 
of lifestyle factors (smoking, drinking), as does 
increasing age (median 60–64 years). Only 1965 of 
the above new cases related specifically to cancer 
of the oropharynx, hypopharynx and larynx.7 A 
recent audit of head and neck cancer treatment, 
specifically that of the oral cavity and larynx, 
indicated that 51% of all patients present with 
early-stage disease, although these figures may be 
skewed by the fact that laryngeal cancer is often 
detected early because of patients presenting with 
voice alteration.5
Prognosis is dependent on many factors, not least 
the origin of the cancer and stage at diagnosis.3 
There is considerable variation in the severity of 
the cancer at diagnosis or presentation. Laryngeal 
cancers have higher 5-year survival rates than oral 
cancers because an obvious symptom of the cancer 
is voice alteration, which often prompts patients 
to consult a doctor earlier than do patients with 
oral cancers, which may only manifest as painless 
ulcers. Ultimately, patients with cancer diagnosed 
and treated at an earlier stage have a much 
better prognosis.3 Treatment usually consists of a 
combination of surgery and radiotherapy and may 
include chemotherapy.3 
Scope of the ERG report
The ERG report critically evaluated the evidence 
submission from Merck Pharmaceuticals on 
the clinical and cost-effectiveness of cetuximab 
(Erbitux®) in combination with radiotherapy 
relative to radiotherapy alone in patients with 
LA SCCHN who are considered inappropriate 
for chemoradiotherapy but appropriate for 
radiotherapy.
Cetuximab in combination with radiotherapy is 
specifically licensed only for the treatment of LA 
SCCHN.8Health Technology Assessment 2009; Vol. 13: Suppl. 1
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Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. The report identified the 
strengths and weaknesses of the manufacturer’s 
submission and presented additional work to 
address issues and uncertainties identified during 
the structured critique of the manufacturer’s 
submission. Simple sensitivity analyses to examine 
the robustness of the results were undertaken by (1) 
examining what change in the average utility value 
for patients in the cetuximab plus radiotherapy 
arm would be required to increase the incremental 
cost per quality-adjusted life-year (QALY) gained of 
cetuximab plus radiotherapy to levels that may not 
be considered cost-effective; the base-case average 
utility in the two groups was identified (ignoring 
discounting) by dividing the estimated QALYs in 
each group by the estimated life-years (Figure 1); 
and (2) examining what change in total average 
costs for the cetuximab plus radiotherapy arm 
would be required, ceteris paribus, for cetuximab 
plus radiotherapy not to be considered cost-
effective (Figure 2).
Results
Summary of submitted 
clinical evidence
One study was included in the submission.9 This 
study was a fully published and well-designed 
and -conducted randomised controlled trial that 
compared radiotherapy plus cetuximab with 
radiotherapy alone in patients with stage III or 
IV non-metastatic squamous cell carcinoma of 
the oropharynx, hypopharynx or larynx. Efficacy 
was evaluated on an intention to treat basis and 
included all randomised patients. Safety was 
evaluated in all patients who received treatment. 
The trial demonstrated that the duration of 
locoregional control (the primary end point) 
was significantly longer with radiotherapy plus 
cetuximab than with radiotherapy alone. With 
respect to secondary end points both overall and 
progression-free survival were significantly longer 
and the overall response rate was significantly 
better with the combination therapy than with 
radiotherapy alone (Table 1). Cetuximab did not 
exacerbate the common toxic effects associated 
with radiotherapy of the head and neck. Severe 
(grade 3–5) acneiform rash and infusion reaction 
occurred more frequently with radiotherapy plus 
cetuximab than with radiotherapy alone, whereas 
the converse applied to severe anaemia.
Summary of submitted cost-
effectiveness evidence
No previous studies were identified by the 
manufacturer or by the ERG that would help 
inform this STA. Therefore, the manufacturer’s 
economic evaluation is considered by the ERG to 
comprise the only relevant evidence to consider for 
the purposes of this STA. 
The manufacturer’s submission included a de 
novo economic evaluation to estimate the cost-
effectiveness of treatment with (1) cetuximab 
plus radiotherapy and (2) radiotherapy alone. 
The economic model (including the comparator) 
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FIGURE 1  Average utility with cetuximab plus radiotherapy and its impact on the incremental cost per quality-adjusted life-year gained 
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FIGURE 2  Average total cost with cetuximab plus radiotherapy and its impact on the incremental cost per quality-adjusted life-year 
gained for the combination therapy. The average cost with radiotherapy alone remains at £7195. ICER, incremental cost-effectiveness 
ratio.
TABLE 1  Efficacy outcomes for the intention to treat (ITT) trial population
Variable
Radiotherapy alone  
(ITT population n = 213)
Radiotherapy plus cetuximab  
(ITT population n = 211)
Locoregional control, median duration 
in months
14.9 24.4
Progression-free survival, median 
duration in months
12.4 17.1
Overall survival, median duration in 
months
29.3 49.0
Response rate (complete response + 
partial response) total number (%)
137 (64%) 155 (74%)
was considered appropriate for the decision 
problem. The results suggested that cetuximab 
plus radiotherapy was cost-effective compared 
with radiotherapy alone under a broad range 
of different assumptions on the basis of a cost-
effectiveness threshold of £20,000. In the base 
case the incremental cost-effectiveness ratio of 
cetuximab plus radiotherapy compared with 
radiotherapy alone in the treatment of patients 
with LA SCCHN was £6390 per additional QALY 
(Table 2).
Commentary on the robustness 
of submitted evidence
The ERG felt that the manufacturer’s submission 
was generally of good quality. There were no 
major errors or omissions and the majority of the 
data quoted within the submission were a fair and 
accurate representation of the original reference 
data. 
The main weakness of the submission was that the 
evidence for the clinical effectiveness of cetuximab 
plus radiotherapy is based on a single clinical trial. 
Therefore, no supporting evidence for the findings 
is available. 
The ERG felt that there were two major areas of 
uncertainty: 
1.  The patient population in the pivotal trial by 
Bonner et al.9 included a high proportion of 
patients who would be expected to be suitable 
for chemoradiotherapy and therefore it does 
not match the population that is the focus 
of the submission’s decision problem, i.e. 
patients who are considered inappropriate 
for chemoradiotherapy. No data are available 
regarding the number of patients in the trial 
who would be considered inappropriate for 
radiotherapy and hence no subgroup analysis 
on the population specified in the decision Health Technology Assessment 2009; Vol. 13: Suppl. 1
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TABLE 2  Incremental cost per quality-adjusted life-year (QALY)
Incremental cost Incremental QALYs
Incremental cost per 
QALY
Cetuximab plus radiotherapy vs 
radiotherapy alone
£6626 1.26 £6390
problem has been carried out. Therefore, the 
trial results may not be directly applicable to 
the target population. However, the clinical 
experts consulted by the ERG were of the 
opinion that the Bonner et al. trial is a good 
source for the comparison of radiotherapy plus 
cetuximab with radiotherapy alone and use 
of the whole trial population is appropriate 
because the factors that would lead to 
chemotherapy being inappropriate are highly 
variable. 
2.  The radiotherapy regimens used in the 
trial are not typical of current UK practice. 
Once-daily radiotherapy is the regimen 
most representative of current UK practice 
(used in about 80% of patients according to a 
survey by the Royal College of Radiologists). 
In the Bonner et al. trial, however, altered 
fractionation regimens (twice daily and 
concomitant boost) were selected for 18% and 
56% of patients respectively (74% in total). 
Another possible area of uncertainty was whether 
there are subgroups of patients who may derive 
more benefit than others from cetuximab with 
radiotherapy. The Bonner et al. trial was not 
powered to detect treatment-related differences 
for subgroups, such as patients who received 
once-daily radiotherapy or those with laryngeal 
or hypopharyngeal cancer,10 but some results 
for subgroups are presented in the published 
paper, although with no confidence intervals 
or p-values. In view of the lack of power of the 
trial, caution needs to be exercised in drawing 
conclusions; however, the results presented raise 
questions as to whether there are subgroups 
of patients who may derive more benefit than 
others from the combination therapy. In patients 
with oropharyngeal cancer, locoregional control 
and overall survival durations appeared to be 
longer than those in patients with laryngeal or 
hypopharyngeal cancer. Furthermore, the once-
daily radiotherapy regimen may have been less 
effective in terms of overall survival than the two 
altered fractionation regimens, and overall survival 
appeared to be longer with radiotherapy plus 
cetuximab than with radiotherapy alone in patients 
who received the concomitant boost regimen. 
Further clinical trials are needed to resolve these 
issues. Details of these subgroup analyses are 
included in the structured critical appraisal of the 
Bonner et al. trial presented in Appendix 3 of the 
full ERG report.2 
Conclusions 
A number of areas of uncertainty emerged in the 
manufacturer’s cost-effectiveness modelling. These 
relate mainly to the extrapolation methods and 
the assumptions used to derive the utility and 
cost estimates. However, based on the sensitivity 
analyses undertaken by the manufacturer and some 
additional ERG analyses, these areas of uncertainty 
are unlikely to have a material effect on the 
conclusions of the cost-effectiveness analysis. 
Future research into establishing which patients 
are likely to derive most benefit from cetuximab in 
conjunction with radiotherapy would be useful, as 
would further research on the clinical effectiveness 
of cetuximab plus radiotherapy in those patients 
with locally advanced SCCHN who are considered 
inappropriate for chemoradiotherapy. Setting 
up a patient register to collect post-treatment 
observational data of patients treated with 
cetuximab may be useful. 
Summary of NICE guidance 
issued as a result of the STA 
The following guidance was issued by NICE in May 
2007:
This guidance on the use of cetixumab in 
combination with radiotherapy, for patients with 
locally advanced squamous cell cancer of the 
head and neck, is based on evidence submitted 
by the manufacturer. The evidence submitted 
was insufficient to enable a recommendation to 
be made on the use of cetuximab in combination 
with radiotherapy, as an alternative in patients 
for whom chemoradiotherapy is inappropriate. 
Cetuximab in combination with radiotherapy is not 
recommended for patients with locally advanced 
squamous cell cancer of the head and neck. People 
currently receiving cetuximab should have the Cetuximab plus radiotherapy for the treatment of LA SCC of the head and neck
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option to continue therapy until they and their 
clinicians consider it appropriate to stop. 
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of infliximab for the treatment of 
moderate to severe plaque psoriasis, in accordance 
with the licensed indication, based on the evidence 
submission from Schering-Plough to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. The outcomes stated in the manufacturer’s 
definition of the decision problem were severity 
[Psoriasis Area and Severity Index (PASI) score], 
remission rates, relapse rates and health-related 
quality of life. The main evidence in the submission 
comes from four randomised controlled trials 
(RCT) comparing infliximab with placebo and 
eight RCTs comparing either etanercept or 
efalizumab with placebo. At week 10, patients on 
infliximab had a significantly higher likelihood of 
attaining a reduction in PASI score than placebo 
patients. There were also statistically significant 
differences between infliximab and placebo in 
the secondary outcomes. In the comparator trials 
both the efalizumab and etanercept arms included 
a significantly higher proportion of patients who 
achieved a reduction in PASI score at week 12 
than the placebo arms. No head-to-head studies 
were identified directly comparing infliximab 
with etanercept or efalizumab. The manufacturer 
carried out an indirect comparison, but the ERG 
had reservations about the comparison because 
of the lack of information presented and areas of 
uncertainty in relation to the included data. The 
economic model presented by the manufacturer 
was appropriate for the disease area and given 
the available data. The cost-effectiveness analysis 
estimates the mean length of time that an 
individual would respond to infliximab compared 
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with continuous etanercept and the utility gains 
associated with this response. The base-case 
incremental cost-effectiveness ratio (ICER) for 
infliximab compared with continuous etanercept 
for patients with severe psoriasis was £26,095 per 
quality-adjusted life-year. A one-way sensitivity 
analysis, a scenario analysis and a probabilistic 
sensitivity analysis were undertaken by the ERG. 
The ICER is highly sensitive to assumptions about 
the costs and frequency of inpatient stays for non-
responders of infliximab. The guidance issued by 
NICE in August 2007 as a result of the STA states 
that infliximab within its licensed indication is 
recommended for the treatment of adults with very 
severe plaque psoriasis, or with psoriasis that has 
failed to respond to standard systematic therapies. 
Infliximab treatment should be continued beyond 
10 weeks in people whose psoriasis has shown an 
adequate response to treatment within 10 weeks. In 
addition, when using the Dermatology Life Quality 
Index (DLQI), care should be taken to take into 
account the patient’s disabilities, to ensure DLQI 
continues to be an accurate measure.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of infliximab for the treatment of moderate to 
severe plaque psoriasis in adults.
Description of the 
underlying health problem
Plaque psoriasis is the most common type of 
psoriasis and is characterised by exacerbations 
of thickened, erythematous, scaly patches of 
skin that can occur anywhere on the body. The 
disease impacts on health-related quality of life. 
The severity of plaque psoriasis can differ in 
individuals; it can be split into mild, moderate and 
severe psoriasis.
Clinical opinion is that the prevalence of moderate 
to severe psoriasis in the UK is around 2%, 
which the ERG would estimate to mean that 
approximately 267,000 people in England and 
Wales have moderate to severe disease. 
The accepted system for classifying the severity 
of psoriasis is the Psoriasis Area and Severity 
Index (PASI). The PASI is not an ideal measure 
of the severity of psoriasis; the limits of PASI are 
well documented,2 but it is the measure used in 
most clinical trials. The guidance for the use of 
biological therapies in psoriasis issued by NICE in 
July 2006 defines severe psoriasis as a PASI of ≥ 10 
combined with a Dermatology Life Quality Index 
(DLQI) of > 10.3 A 2005 review of the PASI as an 
instrument for determining the severity of chronic 
plaque-type psoriasis defines severe psoriasis as 
a PASI of > 12 and moderate psoriasis as a PASI 
ranging from 7 to 12.4 Body surface area (BSA) and 
the DLQI are also commonly used as systems for 
classifying the severity of psoriasis.
Scope of the ERG report
The ERG critically evaluated the evidence 
submission from Schering-Plough for the use of 
infliximab for the treatment of moderate to severe 
plaque psoriasis, in accordance with the licensed 
indication (see below). Infliximab is a tumour 
necrosis factor-alpha (TNF-α) inhibitor which 
affects T-cell functions that involve the release of 
TNF-α and which binds to free TNF-α receptors on 
cell surfaces.
Infliximab is licensed for the treatment of adults 
with moderate to severe psoriasis who have not 
responded to (or who are intolerant of) other 
systemic therapies. 
The outcomes stated in the manufacturer’s 
definition of the decision problem were severity, 
remission rates, relapse rates and health-related 
quality of life.Health Technology Assessment 2009; Vol. 13: Suppl. 1
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Methods 
The ERG report comprised a critical review of 
the evidence for the clinical effectiveness and 
cost-effectiveness of the technology based upon 
the manufacturer’s submission to NICE as part of 
the STA process. The ERG checked the literature 
searches and applied the NICE critical appraisal 
checklist to the included studies, and checked 
the quality of the manufacturer’s submission with 
the Centre for Reviews and Dissemination (CRD) 
quality assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. A one-way sensitivity analysis, 
a scenario analysis and a probabilistic sensitivity 
analysis (Figure 1) were undertaken by the ERG.
Results 
Summary of submitted 
clinical evidence
•	 The main evidence in the submission comes 
from four international randomised controlled 
trials (RCTs) comparing infliximab with 
placebo.5–8 A further eight RCTs were also 
included: four comparing etanercept with 
placebo9–12 and four comparing efalizumab 
with placebo.13–16
•	 Evidence in trials was presented as changes in 
baseline PASI scores, i.e. a PASI 75 refers to an 
individual who had a 75% reduction in their 
baseline PASI score.
•	 At week 10, patients on infliximab had a 
significantly higher likelihood of attaining 
a PASI 75 than placebo patients (range 
75–88% versus 2–18% respectively) (four 
trials). It should be noted that there were 
wide confidence intervals around all four 
point estimates. There was also a statistically 
significant difference at 10 weeks in favour 
of infliximab for the proportion of patients 
achieving a PASI 50 and 90 (three trials).
•	 For both efalizumab and etanercept a 
significantly higher proportion of patients 
achieved a PASI 75 at week 12 compared with 
patients receiving placebo.
•	 In terms of secondary outcomes there were 
statistically significant differences between 
infliximab and placebo in Physician’s 
Global Assessment (PGA) score, DLQI and 
Nail Psoriasis Severity Index (NAPSI). The 
incidence of any adverse event was slightly 
higher in those receiving infliximab compared 
with those receiving placebo, although this was 
not tested statistically. 
Summary of submitted cost-
effectiveness evidence
•	 The cost-effectiveness analysis estimates the 
mean length of time that an individual would 
respond to treatment and the utility gains 
associated with this response. The model is 
based closely upon the model reported in the 
study by Woolacott and colleagues.2 The results 
are presented for infliximab compared with 
continuous etanercept based upon utility values 
for fourth quartile DLQI patients and also for 
all patients.
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•	 The model is generally internally consistent 
and appropriate to psoriasis in terms of 
structural assumptions. The cost-effectiveness 
analysis generally conforms to the NICE 
reference case and the scope/decision problem.
•	 Treatment effectiveness is reported in terms of 
the numbers of patients achieving PASI 50, 75 
and 90 goals at 10–12 weeks and is estimated 
by an indirect comparison using a random-
effects model.
•	 Patients who achieve improvements in PASI 
were assigned an associated improvement 
in quality of life with the higher responses 
associated with larger improvements in quality 
of life. These utility values have been taken 
from a previous report and no information 
was included in the manufacturer’s submission 
on the characteristics of the individuals or the 
methodology used to obtain these values.
•	 The base-case incremental cost-effectiveness 
ratio (ICER) for infliximab compared with 
continuous etanercept for patients with severe 
psoriasis was £26,095 per quality-adjusted life-
year (QALY).
Commentary on the robustness 
of submitted evidence
Strengths
•	 The manufacturer conducted a systematic 
search for clinical effectiveness and cost-
effectiveness studies of infliximab. It appears 
unlikely that any additional trials would have 
met the inclusion criteria had the search been 
widened to include other databases.
•	 The four identified infliximab trials were of 
reasonable methodological quality (with some 
limitations) and measured a range of outcomes 
that are as appropriate and clinically relevant 
as possible.
•	 Overall, the manufacturer’s submission 
presents an unbiased estimate of treatment 
efficacy for infliximab based on the results of 
the placebo-controlled trials.
•	 The economic model presented with the 
manufacturer’s submission used an appropriate 
approach for the disease area and given the 
available data.
Weaknesses
•	 The processes undertaken by the manufacturer 
for screening studies, extracting data and 
applying quality criteria to included studies 
are not detailed in the submission. In addition, 
details relating to the searches were not always 
thorough and were recorded inconsistently. 
These factors limit the robustness of the 
systematic review. 
•	 The manufacturer’s submission reported very 
limited data on the comparator trials and did 
not undertake a systematic review of these.
•	 Combining the four infliximab trials in a 
meta-analysis was not appropriate given the 
statistically significant heterogeneity between 
studies. Similarly, pooling data in the indirect 
comparison was also inappropriate given the 
known heterogeneity. The resulting pooled 
mean values should therefore be treated with 
caution.
•	 The base-case results for the economic model 
have been presented for fourth quartile DLQI 
patients. It is unclear precisely what this 
definition means and how representative this is 
of severe psoriasis patients. 
Conclusions 
Areas of uncertainty
•	 The short intervention period of 10 weeks 
provides limited information about the longer-
term efficacy of infliximab. 
•	 The relative risks calculated by the 
manufacturer have wide confidence intervals 
around all four point estimates for the primary 
outcome of PASI 75 achievement (and other 
outcomes), indicating a lack of certainty 
regarding the true effect.
•	 No description of the principles, assumptions 
or methodology behind the indirect 
comparison was provided, making it difficult 
for the ERG to check either the model or the 
data. Despite asking the manufacturer for 
clarification, a number of areas remain unclear, 
such as where the data come from, which trials 
were included and which placebo groups were 
included for the pooled estimates.
•	 A definition of moderate psoriasis was not 
provided in the manufacturer’s submission 
and neither were there any inclusion/exclusion 
criteria for the rating of the severity of 
psoriasis to ensure that patients were moderate 
to severe. The populations of the included 
infliximab trials were predominantly those with 
severe psoriasis. In addition, it is unclear what 
proportion of trial participants had previously 
been treated with systemic therapy. This causes 
concern over whether the participants included 
in the trials reflect those in the scope.
•	 The PASI is not an ideal measure of the 
severity of psoriasis in terms of measuring 
the impact on patients, but it is often the best Health Technology Assessment 2009; Vol. 13: Suppl. 1
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available outcome and is the measure used 
most in clinical trials. This raises questions 
regarding the relevance of the PASI outcome to 
patient experience in practice. 
•	 There is uncertainty over the appropriate 
group to use in terms of QALY values. The 
base case presents values for fourth quartile 
DLQI patients. It is unclear precisely what the 
characteristics of patients were in this group. 
•	 It was unclear how values for the number of 
inpatient days per year for a non-responder 
were derived. There was also uncertainty over 
the costs associated with inpatient care and 
the number of outpatient stays required for an 
individual on supportive care. 
•	 There may be greater variability in the cost-
effectiveness of treatment than is presented in 
the sensitivity analyses in the manufacturer’s 
submission.
•	 The dropout rate for patients who no longer 
respond may be underestimated in the model.
Key issues 
•	 The trials of infliximab efficacy presented in 
the manufacturer’s submission were placebo-
controlled trials. No head-to-head studies were 
identified that directly compared infliximab 
with etanercept or efalizumab, the comparators 
stated in the scope. The manufacturer 
carried out an indirect comparison but the 
ERG has reservations about the comparison 
because of the lack of information presented 
and areas of uncertainty in relation to the 
included data. In addition, the ERG question 
the appropriateness of pooling data that is 
statistically heterogeneous. 
•	 The ICER is highly sensitive to assumptions 
about the costs and frequency of inpatient stays 
for non-responders of infliximab.
•	 It is unclear what severity of psoriasis was 
represented by the utility values presented 
in the manufacturer’s submission. It is also 
unclear to what extent moderate psoriasis 
would be represented in the analysis presented 
in the submission.
Summary of NICE guidance 
issued as a result of the STA 
NICE issued an appraisal consultation document in 
August 2007 which states that: 
1.1 Infliximab, within its licensed indications, is 
recommended as a treatment option for adults 
with plaque psoriasis only when the following 
criteria are met.
  – The disease is very severe as defined by a 
total Psoriasis Area Severity Index (PASI) 
of 20 or more and a Dermatology Life 
Quality Index (DLQI) of more than 18.
  – The psoriasis has failed to respond to 
standard systemic therapies such as 
ciclosporin, methotrexate or PUVA 
(psoralen and long-wave ultraviolet 
radiation), or the person is intolerant to or 
has a contraindication to these treatments.
1.2 Infliximab treatment should be continued 
beyond 10 weeks only in people whose 
psoriasis has shown an adequate response to 
0 treatment within 10 weeks. An adequate 
response is defined as either:
  – a 75% reduction in the PASI score from 
when treatment started (PASI 75) or
  – a 50% reduction in the PASI score (PASI 
50) and a five-point reduction in the DLQI 
from when treatment started.
1.3 When using the DLQI healthcare 
professionals should take care to ensure that 
they take account of a patient’s disabilities 
(such as physical impairments) or linguistic or 
other communication difficulties, in reaching 
conclusions on the severity of plaque psoriasis. 
In such cases healthcare professionals should 
ensure that their use of the DLQI continues to 
be a sufficiently accurate measure. The same 
approach should apply in the context of a 
decision about whether to continue the use of 
the drug in accordance with section 1.2. 
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